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ABSTRACT
Since the Institute of Medicine highlighted the devastating impact of medical
errors in their seminal report, “To Err is Human” (2000), efforts have been underway to 
improve patient safety. A portion of medical errors are due to medication errors, and a
large portion of these can be attributed to inadequate laboratory monitoring.
In this thesis, I attempt to address this small but important corner of this patient
safety endeavor. Why are patients not getting their laboratory monitoring tests? Do they 
fail to complete them or do doctors not order the tests in the first place? Which 
prescribers and which patients are least likely to do what is needed for testing to happen 
and what interventions would be most promising?
To address these questions, I conducted a systematic review of existing 
interventions. I then proceeded with three aims: 1) To identify reasons that patients give
for missing monitoring tests; 2) To identify patient and provider factors associated with 
monitoring test ordering; and 3) To identify patient and provider factors associated with 
completion of ordered testing.
To achieve these aims, I worked with patients and data at the Fallon Clinic. For 
aim 1, I conducted a qualitative analysis of their reasons for missing tests as well as
reporting completion and ordering rates. For aims 2 and 3, I used electronic medical
record data and conducted a regression with patient and provider characteristics as
covariates to identify factors contributing to test ordering and completion.
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Interviews revealed that patients had few barriers to completion, with forgetting 
being the most common reason for missing a test. The quantitative studies showed that:
older patients with more interactions with the health care system were more likely to have
tests ordered and were more likely to complete them; providers who more frequently 
prescribe a drug were more likely to order testing for it; and drug-test combinations that
were particularly dangerous, indicated by a black box warning, were more likely to have
appropriate ordering, though for these combinations, primary care providers were less
likely to order tests appropriately, and patients were less likely to complete tests. 
Taken together, my work can inform future interventions in laboratory monitoring 
and patient safety.
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix
TABLE OF CONTENTS
COVER PAGE .................................................................................................................... i
 
SIGNATURE PAGE .......................................................................................................... ii
 
ACKNOWLEDGEMENTS............................................................................................... iv
 
ABSTRACT...................................................................................................................... vii
 
TABLE OF CONTENTS................................................................................................... ix
 
LIST OF TABLES............................................................................................................ xii
 
LIST OF FIGURES ......................................................................................................... xiii
 
PREFACE........................................................................................................................ xiv
 
CHAPTER I: INTRODUCTION........................................................................................ 1
 
A. Laboratory Monitoring............................................................................................... 2
 
B. Interventions to Date .................................................................................................. 4
 
C. Ordering and Completion........................................................................................... 4
 
D. Conceptual Model...................................................................................................... 5
 
E. Proposed Study........................................................................................................... 7
 
F. Dataset ........................................................................................................................ 8
 
G. Significance.............................................................................................................. 11
 
H. Specific Aims........................................................................................................... 12
 
I. Summary.................................................................................................................... 13
 
CHAPTER II: THE IMPACT OF HEALTH INFORMATION TECHNOLOGY
 
INTERVENTIONS TO IMPROVE MEDICATION LABORATORY MONITORING
 
FOR AMBULATORY PATIENTS: A SYSTEMATIC REVIEW.................................. 15
 
A. Abstract .................................................................................................................... 16
 
B. Introduction .............................................................................................................. 17
 
C. Methods.................................................................................................................... 19
 
i. Literature Search.................................................................................................... 19
 
ii. Inclusion Criteria and Selection of Studies .......................................................... 19
 
iii. Data Abstraction and Evaluation ......................................................................... 21
 
D. Results...................................................................................................................... 22
 
i. Study Quality and Impact on Laboratory Monitoring ........................................... 24
 
ii. Study Site Characteristics and Impact on Laboratory Monitoring ....................... 25
 
iii. Intervention Design and Impact on Laboratory Monitoring ............................... 26
 
E. Discussion ................................................................................................................ 29
 
CHAPTER III: HIGH-RISK MEDICATION MONITORING TESTS: A MIXED-
METHODS EXPLORATION OF COMPLETION AND BARRIERS ........................... 34
 
A. Abstract .................................................................................................................... 34
 
B. Background .............................................................................................................. 37
 
C. Study Design and Sample ........................................................................................ 39
 
i. Quantitative Analysis............................................................................................. 43
 
ii. Qualitative Analysis.............................................................................................. 44
 
D. Results...................................................................................................................... 47
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x
i. Quantitative Study ................................................................................................. 47
 
ii. Qualitative Results................................................................................................ 50
 
E. Discussion ................................................................................................................ 55
 
i. Forgetting and Reminders...................................................................................... 57
 
ii. Conclusion ............................................................................................................ 59
 
CHAPTER IV: FACTORS ASSOCIATED WITH ORDERING LABORATORY
 
MONITORING OF HIGH-RISK MEDICATIONS......................................................... 61
 
A. Abstract .................................................................................................................... 61
 
B. Background .............................................................................................................. 64
 
C. Methods.................................................................................................................... 66
 
i. Study Design and Setting....................................................................................... 66
 
ii. Selection of Study Medications ............................................................................ 66
 
iii. Medication Exposure ........................................................................................... 69
 
iv. Provider Factors ................................................................................................... 69
 
v. Drug-Test Pair Characteristics .............................................................................. 70
 
vi. Conceptual Framework for Analytic Strategy ..................................................... 72
 
vii. Data Analysis...................................................................................................... 74
 
D. Results...................................................................................................................... 77
 
i. Patient Population and Use of Medications Requiring Laboratory Monitoring.... 77
 
ii. Provider Characteristics........................................................................................ 77
 
iii. Unadjusted Analysis ............................................................................................ 78
 
iv. Multivariable analysis.......................................................................................... 81
 
E. Discussion ................................................................................................................ 84
 
i. Physician Adherence to Guidelines ....................................................................... 85
 
ii. Levels of Evidence ............................................................................................... 87
 
iii. Volume ................................................................................................................ 88
 
iv. Specialists versus Generalists .............................................................................. 89
 
v. Strengths ............................................................................................................... 89
 
vi. Limitations ........................................................................................................... 90
 
vii. Implications for Practice..................................................................................... 91
 
viii. Future Research ................................................................................................. 93
 
ix. Conclusion ........................................................................................................... 94
 
A. Abstract .................................................................................................................... 95
 
B. Background .............................................................................................................. 97
 
C. Methods.................................................................................................................... 99
 
i. Study Design and Setting....................................................................................... 99
 
ii. Selection of Study Medications ............................................................................ 99
 
iii. Medication Exposure ......................................................................................... 100
 
iv. Provider Factors ................................................................................................. 101
 
v. Key Variables...................................................................................................... 101
 
vi. Data Analysis ..................................................................................................... 103
 
D. Results.................................................................................................................... 104
 
i. Patient Population and Use of Medications Requiring Laboratory Monitoring.. 104
 
ii. Provider Characteristics...................................................................................... 105
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi
iii. Unadjusted Analysis .......................................................................................... 105
 
iv. Multivariable Analysis....................................................................................... 108
 
E. Discussion .............................................................................................................. 110
 
i. Adherence ............................................................................................................ 111
 
ii. Tools to Improve Laboratory Monitoring........................................................... 112
 
iii. Strengths and Limitations .................................................................................. 114
 
iv. Future Research ................................................................................................. 115
 
v. Conclusion .......................................................................................................... 115
 
CHAPTER VI: DISCUSSION AND CONCLUSIONS................................................. 116
 
A. Summary of Research Findings ............................................................................. 116
 
B. Strengths and Limitations ...................................................................................... 118
 
C. Future Directions.................................................................................................... 121
 
i. Changing Behavior .............................................................................................. 121
 
ii. Role of Health Information Technology (HIT) .................................................. 123
 
iii. Cost .................................................................................................................... 125
 
D. Final Conclusions................................................................................................... 125
 
BIBLIOGRAPHY........................................................................................................... 127
 
  
  
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
xii
LIST OF TABLES
Table 2.1: Characteristics of Studies Included in the Systematic Review
Table 2.2: Comparison of Serum Potassium Monitoring for Diuretic Use Across
Reviewed Studies
Table 3.1: Age and Gender Characteristics of Study Population vs. U.S. Population Aged 
18 and Older
Table 3.2: Drugs with Recommended Tests and Test Frequencies
Table 3.3: Topics Covered in Qualitative Interviews
Table 3.4: Overall Completion of Indicated Tests for Chronic Users of Study Medications
Table 3.5: Interviewed Patient Characteristics
Table 4.1: Study Medications and Recommended Tests
Table 4.2: Summary of Provider and Patient Characteristics
Table 4.3: Unadjusted Characteristics Associated with Ordering Rate
Table 4.4: Adjusted Model: Factors Associated with Ordering, Including Stratification by 
BBW
Table 5.1: Summary of Provider and Patient Characteristics
Table 5.2: Unadjusted Characteristics Associated with Test Completion
Table 5.3: Adjusted Model for Test Completion
  
  
 
 
 
  
 
 
 
xiii
LIST OF FIGURES
Figure 1.1: Conceptual Model
Figure 2.1: Flow Diagram of Included and Excluded Studies
Figure 3.1: Qualitative Interview Recruitment
Figure 3.2: Completion and Non-Completion of Tests
Figure 3.3: Physician Test Non-Ordering Compared to Patient Non-Adherence
Figure 3.4: Reasons Given for Missed Tests
  
 
 
 
 
  
 
  
  
  
 
  
  
  
 
  
 
 
 
xiv
PREFACE
Publications related to this study but not presented in detail in this thesis are listed as
follows:
Articles
Tjia J, Fischer SH, Raebel MA, Peterson D, Zhao Y, Gagne SJ, Gurwitz JH, Field TS. 
Baseline and Follow-up Laboratory Monitoring of Cardiovascular Medications. The
Annals of Pharmacotherapy. In press, 2011.
Tjia J, Field TS, Fischer SH, Gagne SJ, Peterson D, Garber L, Gurwitz JH. Quality 
Measurement of Medication Monitoring in the ‘Meaningful Use” Era, Under review, 
2011.
Abstracts
Development and Pilot Testing of Guidelines to Monitor High Risk Medications in the
Ambulatory Setting And Post-Hospital Discharge. Tjia J, Field TS, Garber L, Donovan J, 
Kanaan A, Fischer SH, Zhao Y, Fuller J, Gurwitz JH. AHRQ 2009 Annual Conference.
Laboratory Monitoring of High-Risk Cardiovascular Drugs in the Ambulatory Setting: 
The Relative Contribution of Physician and Patient Behavior to Undermonitoring. 
Fischer SH, Tjia J, Field TS, Raebel MA, Zhao Y, Garber L, Donovan J, Kanaan A, 
Gagne SJ, Gurwitz JH. AHRQ Annual Health IT Grantee and Contractor Meeting, 2010.
Why Patients Fail to Complete Ordered Laboratory Monitoring. Fischer SH, Gagne SJ, 
Preusse P, Mazor K, Field TS, Tjia JT. HMORN Conference, 2011.
Quality Measurement Issues in the Era of Meaningful Use: Lessons from the Laboratory
Monitoring of High-Risk Medications. Tjia JT, Field TS, Fischer SH, Gagne SJ, Peterson 
D, Gurwitz JH. HMORN Conference, 2011.
Parents’ Role in Specialty Referrals: Views from Both Sides of the Exam Table. Fischer 
SH, Cooley WC, Mazor KM, Dworetzky MS, Stille CJ. PAS/ASPR Joint Meeting, 2011.
Abstract selected for oral presentation at 2011 Pediatric CARE conference in Monterey, 
CA, February 2011 and selected for a platform presentation at PAS/ASPR Joint Meeting, 
2011.
  
 
 
 
 
 
 
  
 
  
 
 
 
 
  
 
 
 
 
1
CHAPTER I
INTRODUCTION
“Between the health care we have and the care we could have lies not just a gap, but a
chasm.” – IOM: Crossing the Quality Chasm1 
Medicine has made amazing progress in the past century. At the turn of the 20th 
century, penicillin had not been discovered, anesthesia was in its early stages, and 
maternal mortality was at about 1 in 100. We now have advanced technology, from
robotic surgery to targeted radiation, a wealth of medications including monoclonal
antibodies and antiretroviral drugs, and maternal mortality has declined by two orders of
magnitude.
However, at the turn of this new century, the medical world uncovered a terrible
truth. While much of our medicine was saving lives, we were also causing numerous
deaths via medical errors. The Institute of Medicine’s “To Err is Human” (2000)2 
estimated there were 44,000 to 98,000 deaths per year from medical errors in the US, 
while “The Quality Chasm” (2001)1 offered guidelines as to how to achieve a better 
system, calling for care that is safe, effective, patient-centered, timely, efficient, and 
equitable, together galvanizing the medical community to face the problem of medical
errors.
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A major portion of the medical errors described in these studies are medication 
errors, and 60.8% percentage of preventable adverse drug events (ADEs) in the
ambulatory setting are associated with medical errors due to inadequate laboratory 
monitoring of high-risk medications.3, 4 Among preventable ADEs requiring hospital
admission, the most frequent drug therapy problem was inadequate monitoring (45.4%).5 
In the inpatient environment, errors have been shown to occur most often during ordering 
and administration6 However, while we know the process differs in the outpatient setting, 
we have less information on ADEs in this setting,7 though it is where most drugs are
prescribed.
This thesis studies failures in laboratory monitoring of high-risk drugs in the
ambulatory setting as a contribution to the improvement of the problem of medical errors.
A. Laboratory Monitoring
When we refer to laboratory monitoring, we include monitoring that addresses
both safety and efficacy. Many medications require monitoring of symptoms or test
results to prevent toxicity or to monitor efficacy. For medications with narrow therapeutic
windows, such as digoxin or antiepileptics, serum drug levels are monitored to reduce the
risk of toxicity. For other medications, monitoring evaluates the physiologic effect of
medications, either for side effects or for effectiveness; for example, angiotensin-
converting enzyme inhibitors can cause elevated potassium and creatinine levels, while
thyroid function tests are conducted regularly for those on thyroid hormones to ensure
appropriate dosing. For some drugs, such as carbamazepine or lithium, monitoring 
involves measuring both drug levels and physiologic effects.8 
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Evidence has shown that inadequate monitoring is due both to inadequate
ordering as well as to patient non-attendance once a test is ordered.9 However, separating 
monitoring failures due to lack of ordering (where the provider did not place an order for 
a monitoring test) versus those due to patient non-adherence (where the patient did not
complete an ordered test) requires information beyond the scope of data typically 
captured from administrative claims alone. In studies of laboratory monitoring, generally 
only test completion rates have been reported from administrative claims,10-13 meaning 
that a test was either both ordered and completed, or that it was not ordered and 
completed, but the reason for the failure is not clear. However, when electronic medical
records are used, a distinction can be made between the test ordering rate and test
completion rate, and in some cases ordering rates have been reported;14, 15 occasionally, 
but rarely, both are available.9, 16 In addition to trying to identify a root cause, reporting 
these two factors separately provides potential for better quality measurement: rather than 
reporting simple completion rates, provider behavior can be evaluated.17 
This is a major advantage of using electronic medical record systems to study this
topic. As has been shown elsewhere, combining laboratory and medication data allow for 
evaluating the quality of treatment, studying adverse events, and investigating drug-test 
interference.18, 19 Furthermore, electronic systems have the potential to improve outcomes
and lower costs.20 Computerized physician order entry (CPOE) and clinical decision 
support (CDS) have been shown to be effective in reducing medication errors.21, 22 
However, much less is known about the role of similar systems in improving laboratory 
monitoring rates.
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B. Interventions to Date
A systematic review I conducted in preparation for this thesis research identified 
eight studies studying health information technology interventions targeting laboratory 
monitoring.23 This review appears in Chapter II. In brief, I found that the results of the
studies were inconsistent at best, perhaps due to variations in design. Five of the eight
studies reported statistically significant improvements in laboratory monitoring 
attributable to the study intervention.9, 10, 13, 15, 24 We reported concern regarding the
design of some studies (not all were randomized controlled trials10, 15) and the analytic
approach (some were not successfully randomized before the intervention, while most
failed to account for clustering and confounding in their analysis9, 10, 12, 13, 15), leading us
to conclude that additional well-designed and rigorously analyzed studies are necessary. 
Another review of recent studies came to the same conclusion.25 
C. Ordering and Completion
Before embarking on another intervention to improve laboratory monitoring in the
ambulatory setting, it is important to identify the factors associated with poor monitoring 
in the first place. As we will show, the research on factors associated with ordering and 
with completion of laboratory testing in the ambulatory setting is very limited.
We know that some missed laboratory tests are due to non-ordering and others
due to non-completion, but the literature has not identified the reasons or associated 
factors for each. First of all, we do not know why patients miss ordered laboratory 
testing. Providers have been interviewed about when ordering of recommended tests does
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not occur,26 but patients have not been asked the same questions about their attendance. 
In Chapter III, we describe our study interviewing patients about their reasons for not
completing ordered laboratory tests.
Past research has also shown poor provider adherence to guidelines.27 In Chapter 
IV, we examine provider and patient factors and provider ordering in an attempt to 
identify those factors associated with ordering.
Similarly, there is good evidence for poor patient medication adherence28 and 
poor appointment attendance,29 but the data is sparse regarding laboratory testing 
completion, especially separated from ordering behavior. In Chapter V, we examine
provider and patient factors associated with completion of ordered tests.
D. Conceptual Model
The initiating event in our conceptual model is the prescription of a high-risk 
medication. Based on provider characteristics, a test may or may not be ordered. Once
ordered, a test may or may not be completed. As a result, outcomes occur at different
rates. I examined each step in this process to determine factors that affect the branches in 
the decision tree using a theoretical framework from Andersen.30, 31 
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Figure 1.1: Conceptual Model
Anderson’s model of health services use can be used to guide inquiry into the
association between patient and physician factors and recommended laboratory 
monitoring of prescription medications. This model, which guides our approach to this
study, generally looks at the behavior of patients and families, and it classifies predictors
of behavior into three categories: predisposing factors refer to demographic factors like
age and gender as well as family structure and health beliefs that affect service use;
enabling factors include resources that promote or inhibit use like income and health 
insurance; and needs factors, which comprise the illness and circumstances that
necessitate use.30, 31 
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I expected predisposing factors to affect both patient and physician behavior. For 
example, education and gender could be predisposing factors within both groups. Among 
patients, I expected differences based on number of medications. Among providers, 
specialty, years in practice, and provider type (physician versus nurse practitioner versus
physician assistant) may affect behavior. Other factors that contribute to provider 
behavior may include past experiences with adverse events from failing to test for a
specific drug, but those historical experiences are hard to measure with electronic data.
An enabling factor for patients could be frequency of clinical visits. Years at
Fallon Clinic may be an enabling factor for physicians since it would affect familiarity 
with the records system. Frequency of prescribing is another factor that will likely affect
test ordering, as providers expected to be more familiar with more frequently prescribed 
medications. 
Current medical conditions and overall health status of the patient are the needs
factors that drive health care use in general and need for laboratory monitoring 
specifically.
These determinants of behavior are expected to affect health behavior, in 
Andersen’s model, which in turn should affect health outcomes.
E. Proposed Study
To gain further insight for development of improvements to laboratory monitoring 
in the ambulatory setting, I proposed a retrospective cohort study, examining the factors
associated with inadequate monitoring prior to a randomized controlled trial of a health 
information technology (HIT)-based transitional care intervention. The data source is
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Fallon Clinic, which uses Epic, the EpicCare Ambulatory electronic medical record 
(EMR), for all of their laboratory testing and results. Epic conforms to interoperability 
standards and meets a comprehensive set of criteria for functionality, interoperability, and 
security. Epic can be customized according to the specific needs of the local clinical site. 
I proposed to examine a selected list of high-risk medications and associated 
recommended monitoring and study the association of test ordering and completion with 
various patient and provider factors.
Furthermore, although estimates suggest that up to 95% of potential adverse drug 
events can be avoided with the adoption of advanced computerized systems,32 it is
humans who use the technology, and humans will always make some errors. 
Understanding human factors is an essential component of designing systems to reduce
errors. Therefore, I also proposed a qualitative study to examine patient reported factors
associated with failing to complete ordered tests.
F. Dataset
There are two sources of data for this project: 1) the Fallon Clinic electronic
medical record (EMR), EpicCare Ambulatory EMR system (Epic, Verona, WI, Spring 
2007 IU3 at the time of the study) and 2) Fallon Community Health Plan (FCHP) claims
and utilization databases. All data used encoded patient and physician identifiers.
Epic is a widely used EMR system certified by the Certification Commission for 
Healthcare Information Technology (CCHIT). Access to Epic is available using computer 
terminals throughout the inpatient and outpatient settings, and is also accessible off-site. 
All practitioners are trained on the documentation and order-entry system and are
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supported by Epic training staff. Clinical data in the system are entered by medical staff. 
Registration data are entered by clinic staff. Clinical data are entered by medical
assistants at the beginning of a visit and then completed by the provider. Lab tests orders
are recorded when placed by providers. Results are automatically recorded into the
patient record via internal systems when results are available. Patients do not enter any 
data into the Epic record. Epic contains information about physician diagnoses, radiology 
and lab reports, medications, and notes. The paper medical chart is also available at the
primary care physician’s office for further historical and in-depth data. Finally, 
automated databases include FCHP claims databases on services utilized by patients and 
Clarity databases on clinical encounters, procedures, and labs at Fallon Clinic and Saint
Vincent Hospital/Worcester Medical Center.
The laboratory medication monitoring system and process currently in place
Currently, there are no electronic or other reminders in place to physicians
regarding laboratory testing at the multispecialty group practice with which we worked. 
The process of laboratory monitoring to ensure the safety and effectiveness of drug 
therapy at this practice is similar to that in other ambulatory clinical settings. At the time
when the data was collected, Epic tests that were ordered but not completed within a 25% 
time frame past the date set at time of ordering appeared in a “no-show” file for data
purposes. However, reminders were not being issued to patients or to providers.
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The importance of linked laboratory and pharmacy data
Without electronic tools, it is difficult to identify the reason for low completion of
testing. When laboratory data are separate from medication data, test order rates cannot
be compared to prescribing rates. The absence of a computerized system that links
laboratory and medication information can lead to increased prescription errors and 
decreased quality of care.18, 19, 33, 34 Linking this data is important for studying adverse
events.18, 35-37 Combining the data can reveal patients inappropriately treated given a
physical condition, such as with potassium while hyperkalemic; can reveal conditions
that require treatment, such as untreated elevated TSH; can identify the need for dose
adjustments, given renal insufficiency, for example; can monitor toxicity, such as liver or 
kidney damage; and can measure efficacy.18 Even in places with electronic ordering of
tests, it is often difficult to track which tests are not completed.33 
Combined data in electronic records can be used to improve testing rates with 
reminders to physicians as well as to generate reminders for patients, whether directly or 
through a system that generates letters or calls, at the time that will be most effective for 
patients. Relevance and timing of reminders are central to good informatics, or as the
“Ten Commandments” of decision support put it, “applications must anticipate clinician 
needs and bring information to clinicians at the time they need it,”38 and this principle
applies to interventions directed at patients as well. Without EMRs, it is hard to achieve
this level of coordination and personalization. Our access to EMR data allowed us to 
conduct this study.
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Human subjects
The study protocol and all the study materials to be used in this project have been 
approved by the institutional review boards of the University of Massachusetts Medical
School and the multispecialty group practice where the research was conducted.
G. Significance
The results of this study will inform the design of future interventions to improve
laboratory monitoring. Attempts have been made to improve monitoring, the more recent
of which have often used computerized systems or electronic reminders. There is reason 
to expect that CDS with CPOE could improve recommended monitoring as CDS systems
have been shown to improve patient care and clinical outcomes.39 Patient interventions
have also been attempted such as automated voice messaging or nurse phone calls.24 
However, interventions intended to improve laboratory monitoring have thus far had 
varied success.10-12, 14, 24 In order to develop the most effective interventions, there needs
to be a clearer understanding of what patient factors actually contribute to poor 
monitoring, both by looking across patient populations and also by speaking to patients
directly about their experiences. Targeted interventions to specific patients can make
interventions more effective, as has been shown with appointment non-attendance.40 
Furthermore, studies that have distinguished between ordering and completion rates show
that inadequate monitoring results from both a failure to order the test and the failure to 
complete ordered tests, so provider factors also need to be examined. This study will
identify the populations most at risk for inadequate monitoring as well as provider 
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characteristics associated with not ordering recommended tests in order to inform
targeted intervention strategies.
H. Specific Aims
Therefore, the following specific aims and associated hypothesis were proposed for this
thesis project:
Aim 1
Using qualitative methods, to identify patient-reported factors associated with non-
completion of ordered laboratory tests.
Hypothesis: Patient factors that are not available in the electronic record may 
significantly contribute to missing laboratory tests. To this end, I conducted a series of
interviews with patients to examine factors that contribute to non-completion of ordered 
laboratory tests, as factors that may not be determined from our quantitative studies, but
which may well be modifiable, could account for some missed laboratory tests, such as a
patient’s lack of understanding of the reason for the test. Patient non-completion and 
provider non-ordering rates were also reported for study medications. The study 
conducted and its results are described in Chapter III.
Aim 2
To identify provider factors associated with ordering of laboratory monitoring, adjusting 
for level of test evidence and patient characteristics.
Hypothesis: One factor that contributes to inadequate laboratory monitoring is that
recommended tests are not ordered. Some providers are less likely than others to order 
laboratory testing on the same medication. Familiarity with a medication, specialty, and 
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strength of the guideline driving the testing, among other factors, may contribute to 
variation among ordering rates. Patient factors must be accounted for as well. The study 
conducted and its results are described in Chapter IV.
Aim 3
To identify patient factors associated with completion of ordered tests, adjusting for 
provider characteristics.
Hypothesis: In addition to low ordering rates, another factor that contributes to 
inadequate laboratory monitoring is patient non-completion of laboratory testing that has
been ordered. Demographic factors, including age, sex, medical condition and presence
of certain diagnoses; number of study medications; and frequency of medical
appointments were analyzed. Provider factors may also influence completion rate, so 
selected provider factors need to be accounted for as well. The study conducted and its
results are described in Chapter V.
I. Summary
Lack of recommended laboratory monitoring has been identified as a major 
category of medical errors and is a source of preventable serious adverse drug events. 
The long-term goal of this study is to provide information about patients on high-risk 
medications and the physicians who order these medications in order to inform
interventions to improve monitoring rates. Furthermore, speaking with patients directly 
can elucidate other reasons for missing opportunities for laboratory monitoring for high-
risk medications.
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Ultimately, our hope is to contribute to the process of improving our health care
system. If patients on high-risk medications are better monitored, we can reduce adverse
events and ensure that the health care system is solving, rather than creating, medical
problems.
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CHAPTER II
 
THE IMPACT OF HEALTH INFORMATION
 
TECHNOLOGY INTERVENTIONS TO IMPROVE 

MEDICATION LABORATORY MONITORING FOR
 
AMBULATORY PATIENTS: A SYSTEMATIC REVIEW
 
This chapter was previously published as:
Fischer SH, Tjia J, Field TS. Impact of health information technology interventions to 
improve medication laboratory monitoring for ambulatory patients: a systematic review. 
Journal of the American Medical Informatics Association. Nov 1 2010;17(6):631-636. 
doi:10.1136/jamia.2009.000794 
Reproduced with permission from BMJ Publishing Group Ltd.
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A. Abstract
Medication errors are a major source of morbidity and mortality. Inadequate laboratory 
monitoring of high-risk medications after initial prescription is a medical error that
contributes to preventable adverse drug events. Health information technology (HIT)-
based clinical decision support may improve patient safety by improving the laboratory 
monitoring of high-risk medications, but the effectiveness of such interventions is
unclear. Therefore, we conducted a systematic review to identify studies that evaluate the
independent effect of HIT interventions on improving laboratory monitoring for high-risk 
medications in the ambulatory setting using a MEDLINE search from January 1, 1980 
through January 1, 2009 and a manual review of relevant bibliographies. We excluded all 
anticoagulation monitoring studies. Eight articles met our inclusion criteria, including 6 
randomized controlled trials and 2 pre–post intervention studies. Six of the studies were
conducted in 2 large, integrated health care delivery systems in the United States. 
Overall, five of the eight studies reported statistically significant, but small, 
improvements in laboratory monitoring; only one-half of the randomized controlled trials
reported statistically significant improvements. Studies that found no improvement were
more likely to have used analytic strategies that addressed clustering and confounding. 
Whether HIT improves laboratory monitoring of certain high-risk medications for 
ambulatory patients remains unclear, and further research is needed to clarify this
important question.
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B. Introduction
Since the Institute of Medicine (IOM) highlighted the impact of medical errors on 
patient morbidity and mortality in “To Err is Human,”2 significant effort has focused on 
reducing medical errors and improving patient safety in the United States. Medical errors
result in 44,000 to 98,000 deaths per year, a large proportion of which are due to adverse 
drug events (ADEs).2 Laboratory monitoring errors are a major cause of potential ADEs, 
occurring in 60.8% of preventable ADEs in ambulatory older adults3 and in 45.4% of
preventable ADEs requiring hospital admission.5 Baseline monitoring rates are low, with 
up to 58% of initial drug dispensings occurring without appropriate lab monitoring for 
ambulatory older adults.41 Because patients sometimes miss more than one test for a
given drug and often take many drugs, the rate of all potential laboratory-monitoring 
errors was estimated to be extremely high (~80%) among patients taking chronic
medications in 2001.42 Because poor adherence to guidelines leads to hospitalizations and 
significant morbidity,5, 11 and because basic human factors make it challenging for 
clinicians to adhere to complicated monitoring recommendations for a large number of
medications, health information technology (HIT) holds promise for improving 
laboratory monitoring of high risk medications and may potentially reduce medication 
32, 43 errors.
Some experts estimate that up to 95% of potential ADEs can be avoided with the
adoption of advanced computerized systems.32 As a result, tools to reduce errors continue
to be developed, many of which are technology-based. However, the actual impact of
these systems is unclear. Technology and clinical decision support (CDS) systems have
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been shown to improve patient care and clinical outcomes in many clinical situations.39 
For example, computerized physician order entry with decision support can reduce 
medication errors,21 and interventions to improve laboratory-monitoring in the hospital
setting can improve outcomes44. Furthermore, computer access to laboratory data
improves the opportunity for pharmacists to monitor medications,22, 45 and systematic
reviews of interventions to improve monitoring in the hospital setting show that HIT can 
reduce errors.21, 46-48 Unfortunately, it remains unclear whether HIT CDS alerts in the
ambulatory setting are as effective. 
To address this gap in the literature, we conducted a systematic review to identify 
studies that evaluated HIT interventions to improve laboratory monitoring of selected 
high-risk medications in the ambulatory setting. The specific aims of this review are to 
answer the following questions regarding high-risk medications (excluding 
anticoagulants) in the ambulatory setting: (1) Do HIT interventions improve laboratory 
monitoring?, and (2) What are characteristics of HIT interventions that improve
monitoring? This review should inform the planning of laboratory monitoring 
interventions and guide future researchers about important research design elements for 
HIT interventions.
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C. Methods
i. Literature Search
To identify journal articles for this systematic review, we performed a Medline
search of English-language human studies published between January 1, 1980 and 
January 1, 2009 using keywords for HIT and drug monitoring.
The search performed was as follows:
(“drug monitoring” OR “laboratory monitoring”) AND (computerized OR 
electronic OR informatics OR reminder systems OR “Medical Records Systems, 
Computerized”[MeSH] OR “Decision Support Systems, Clinical”[MeSH] OR 
“Decision Making, Computer-Assisted”[MeSH] OR “Database Management
Systems”[MeSH])
We performed a manual review of relevant authors and journals including 
bibliographies from identified articles.
ii. Inclusion Criteria and Selection of Studies
We included studies that: were clinical trials, randomized controlled trials
(RCTs), or comparative studies; were conducted in an ambulatory setting; had sufficient
information about the HIT intervention for it to be assessed separately from other non-
HIT interventions; and examined laboratory test monitoring rather than clinical tests (e.g., 
pulmonary function tests). We included studies evaluating the effect of HIT interventions
on laboratory test monitoring, defined as laboratory tests to evaluate efficacy, toxicity, or 
side effects. We excluded studies that examined laboratory testing to evaluate medication 
adherence, computerized order interventions that did not include laboratory monitoring, 
at-home patient testing, in-hospital interventions, and literature reviews, meta-analyses, 
case studies, and opinion pieces. We also excluded studies in which the HIT monitoring 
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intervention was coupled with other interventions (e.g., HIT-based medication dosing and 
appointment scheduling recommendations) because it was not possible to identify the
independent effect of HIT on laboratory monitoring; this included all studies evaluating 
anticoagulation interventions and several multipronged diabetes interventions. Additional
studies identified from bibliographies and author searches were also evaluated for 
inclusion based on the same criteria.
The literature search produced 347 abstracts, of which 314 were in English and 
published from January 1, 1980 to January 1, 2009 (Figure 2.1). Each study was assessed 
independently by two investigators (SHF and JT) for inclusion. Disagreements were
resolved by consensus. There were 256 studies after exclusion of review articles, and 
most were excluded after manual review for not meeting the inclusion criteria. Many 
studies were excluded for more than one reason, such as not being an actual trial and 
covering a topic other than laboratory monitoring.
Figure 2.1: Flow Diagram of Included and Excluded Studies
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iii. Data Abstraction and Evaluation
We extracted data from the text and tables of the original publications and 
classified by clinical setting, targeted medications, time frame, HIT intervention type and 
duration, randomization, comparison group, and endpoint assessed. In one case
investigators contacted a study author for additional results. 
Quality scores were assigned by two investigators (SHF and JT) using an 
approach outlined by Downs et al.49 to assess methodological quality. This approach 
standardizes and rates important aspects of study design and data presentation to assign 
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an overall study quality rating score. The maximum score possible for an original
investigation was 27. Disagreements were reconciled by consensus.
D. Results
A detailed review of the potentially eligible articles identified a total of 8 articles
for inclusion that evaluated the impact of HIT interventions on laboratory monitoring in 
the ambulatory settings published between 2003 and 2009. A brief description of these
studies is presented in Table 2.1.
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Table 2.1: Characteristics of Studies Included in the Systematic Review
Author Date
published
Study type Intervention Study Location Sample size Score Unit of
analysis
Confoundin 
g and 
clustering 
in analysis
Outcome
measured
Results (+: statistically significant
change in monitoring rate / –: no
effect of the intervention on the 
monitoring rate)
Feldstein24 2006 RCT - cluster-
randomized by
clinic
EMR reminder via
email as well as 
two other
interventions
OR - Kaiser
Permanente
HMO, 15
primary care
clinics
44 PCPs with 
196 patients in 
EMR arm
25 Patient Yes Completed
monitoring
+: EMR reminder ! baseline laboratory
monitoring of 10 medications, from 
22 4% to 48 5%: 26 1% absolute
!/116% relative !; HR of 2 5, but less
effective than voice message or
pharmacy outreach
Hoch10 2003 Pre–post , no 
control
EMR reminder via
email
Israel - HMO 504 physicians 18 Patient No Completed
monitoring
+: Reminders to clinicians ! potassium
testing (78 5"81 5%; 3 0% absolute
effect; 9 8% relative; p<0 001)
Lo14 2009 RCT EMR reminder MA - Partners
HealthCare
22 primary care
clinics: 3673
events among 
2765 patients
23 Clinic visit Yes Ordering –: Reminders did not improve ordering
of laboratory monitoring significantly
Matheny11 2008 RCT EMR reminder MA - Partners
HealthCare
1,922 patients
seen by 303
physicians in 
2,507 clinic
visits
24 Clinic visit Yes Completed
monitoring
–: Reminders did not improve laboratory
monitoring significantly
Palen12 2006 RCT EMR reminder CO - Kaiser
HMO
207 PCPs with11,
14 104 in the
intervention arm
caring for 26,586
patients
22 Dispensing
(first)
No Completed
monitoring
–: Reminders did not improve laboratory
monitoring significantly Significant
improvement for selected medications
Raebel9 2005 RCT Pharmacists
reminded
electronically
about missing tests 
and then ordered
them and reminded
patients
CO - Kaiser
HMO
10,169 drug 
dispensings for
9,565 patients
23 Dispensing
(each unique
initial drug
dispensing)
No Completed
monitoring
+: Statistically significant ! monitoring
in the intervention group, varying
widely by medication (70 2"79 1%
overall; 8 9% absolute effect; 12 6%
relative; p< 001)
Raebel13 2006 RCT Pharmacists
reminded
electronically
about missing tests 
and then ordered
them and reminded
patients
CO - Kaiser
HMO
9,139 patients
with 4,871
patient-drug 
combinations
22 Patient-drug 
combination
(ongoing
therapy)
No Completed
monitoring
+: Statistically significant improved 
monitoring in the intervention group for
only some of the medications (58"64%
overall; 6% absolute effect; 10%
relative; p<0 001)
Steele15 2005 Pre–post, no 
control
EMR reminder CO - Safety net 
outpatient clinics
Rule processed
16,291 times;
19,076 patients
seen during the 
time period
16 Orders No Ordering +: Increased ordering of the rule-
associated laboratory test when an alert
was displayed (39"51%; 12% absolute
effect; 31% relative; p < 0 001)
Abbreviations: !, increase; CO, Colorado; EMR, electronic medical record; HMO, health maintenance organization; HR, hazard ratio; MA, Massachusetts; OR, 
Oregon; PCP, primary care physician; RCT, randomized controlled trial.
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Seven studies were conducted in the United States9, 11-15, 24 and one in Israel.10 Six of
the eight studies were conducted in large, integrated health care delivery systems9, 11-14, 24, 
including a series of studies by Raebel, et al. at Kaiser Permanente9, 12, 13, 24 and two studies at
Partners HealthCare.11, 14 Five interventions sent electronic alerts to prescribing physicians
alone.10-12, 14, 15 Three sent electronic alerts to a pharmacist who could then order the laboratory 
test and contact the patient.9, 13, 24 One of the three studies that involved pharmacists also 
included a comparison arm of computerized alerts to physicians only.24 Seven studies targeted a
broad range of medications,9, 11-15, 24 while the eighth targeted a single medication.10 Six studies
evaluated completion of laboratory test monitoring as the outcome measure,9-13, 24 while two 
evaluated physician test ordering.14, 15 A meta-analysis of the data reported was deemed 
inappropriate due to the differences between the studies.
Five of the eight studies reported statistically significant improvements in laboratory 
monitoring attributable to the study intervention,9, 10, 13, 15, 24 whether an improvement in 
appropriate tests ordered or a increase in the completion rate, with the absolute percent
improvement ranging from 3.0% to 26.1%. There was no consistent pattern of intervention 
efficacy based on outcome measurement. The number of patients enrolled in each study ranged 
from 196 to 26,586. The smallest study showed the largest absolute improvement in 
monitoring.24 
i. Study Quality and Impact on Laboratory Monitoring
Six of the eight studies were RCTs, while 2 were pre–post intervention studies. A brief
description of the study methodologies and quality rating score is included in Table 2.1. The
study quality rating scores ranged from 16 to 25 (possible score range 0 – 27). The RCTs were
rated higher (quality score = 22-25) than the pre–post intervention studies (quality score = 16-
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18). Studies with the highest scores differed from lower quality studies in their analytic
approaches by including adjustment for confounding and clustering.11, 14, 24 Interestingly, 
randomization failed in two of the highest quality studies,11, 14 where the intervention and control
groups were significantly different on key clinical characteristics such as gender, race, and 
insurance type.
Both pre–post studies showed statistically significant improvements,10, 15 while only three
of the six RCTs did.9, 13, 24 All of the RCTs that showed improvements involved pharmacist-
based interventions; this included the only RCT that showed improvement by an alert targeting 
physicians, and this intervention was evaluated as the comparison arm for more intensive
pharmacist-based intervention.24 
All studies enrolled patients nested within providers; two multi-site studies were cluster 
randomized trials at the level of the clinic, nesting providers within each site.14, 24 Three studies
accounted for clustering at the level of the clinic or provider in the analyses or design,11, 14, 24 and 
two of these reported no improvements in monitoring with HIT intervention.11, 14 While all
studies listed some possible patient-level or facility-level confounders, only the same three
studies adjusted for these possible confounders in their analyses,11, 14, 24 and two of these studies
showed no intervention improvements.11, 14 Additionally, of the six RCTs, the three RCTs with 
failures in randomization reported no improvement in monitoring, after any adjustment.11, 12, 14 
ii. Study Site Characteristics and Impact on Laboratory Monitoring
Six of the eight studies were conducted in one of two large integrated healthcare delivery 
systems, Kaiser Permanente and Partners HealthCare; these included all of the RCTs.9, 11-14, 24 
One study was conducted in a safety-net clinic,15 and one study in multiple health maintenance
organization sites in Israel.10 Baseline rates of appropriate laboratory monitoring varied between 
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study sites, ranging from 14%11 to greater than 95%9 depending on the study drug. Sites with 
lower baseline rates of monitoring reported greater improvements associated with HIT
interventions.13, 15, 24 Both studies from Partners HealthCare showed no improvements with HIT
interventions, but had high baseline rates of monitoring prior to the intervention.11, 14 The safety-
net clinic study and the Israeli HMO study had different baseline levels (38.5% and 78.5%) but
both showed significant monitoring improvements in their pre–post intervention assessments.10,
15 
iii. Intervention Design and Impact on Laboratory Monitoring
All the studies were conducted within health care systems with electronic records. Four 
interventions were based on homegrown electronic medical records programs10-12, 14 while four 
were based on modifications to proprietary systems.9, 13, 15, 24 Six of the eight interventions were
built in systems with computerized physician order entry (CPOE), with the alert going to the
physician. Of these, two sent messages via email,10, 24 while four provided alerts during patient
profile reviews.11, 12, 14, 15 
Of the CPOE interventions, alerts within the electronic record system were either 
interruptive (requiring the provider to respond to the alert) or non-interruptive (not requiring 
action). In one study, the intervention was interruptive and required action on the part of the
provider to dismiss an alert;15 however, this intervention did not shorten the process of test or 
medication ordering. Other studies had real-time alerts that appeared on the prescribing page as a
warning, but they were non-interruptive and did not stop the workflow.11, 12, 14 No aspect of the
CPOE design itself was found to be consistently more effective than any other. Interestingly, the
two studies that alerted pharmacists directly, but not physicians, demonstrated significant
improvements in monitoring.9, 13 
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Most interventions reviewed targeted multiple high-risk medications, while one
involved only a single drug.10 When we examined the impact of interventions on the same drug, 
diuretics, across all the studies, we found no significant effect of the HIT intervention except in 
the study for which this was the only drug targeted.10 (Table 2.2) There was no consistency 
between the medications targeted and whether there was a significant intervention effect.
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Table 2.2: Comparison of Serum Potassium Monitoring for Diuretic Use Across Reviewed Studies
Study Drug Outcome
Measure
Effect Measurement Effect Size Confidence
Interval
P -
value
Pre-
intervention
monitoring
rate or 
control
group
Post-
intervention
monitoring
rate or 
intervention
group
Feldstein24 All diuretics* K testing Hazard ratio 0.9* 0.70-1.10 0.24
Hoch10 All diuretics K testing Absolute % increase
prevalence of testing
3.0% <0.001 78.5% 81.5%
Lo14 All diuretics K Adjusted odds ratio‡ 1.32 0.87-2.023 0.20
Matheny11 Potassium
sparing diuretic
K Odds ratio 0.82 0.12-5.60 0.84 60.7% 68.4%
Matheny11 Thiazide diuretic K Odds ratio 1.30 0.63-2.67 0.47 51.7% 64.5%
Palen12 All diuretics K Absolute % increase
prevalence of testing
1.60% 0.11 44.0% 45.6%
Steele15 Diuretics not
reported
separately
n/a n/a n/a n/a n/a n/a n/a
* Not specific to diuretics, but embedded in composite measure for non-ACE/ARB drugs
‡ Corrected numbers based on correspondence with the authors
Abbreviations: ACE, Angiotensin-Converting Enzyme Inhibitors; ARB, Angiotensin II Receptor Blockers; HR, hazard ratio; K, Potassium; OR, odds ratio 
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E. Discussion
By 2009, eight studies reported the results of HIT interventions to improve
laboratory monitoring of medications in the ambulatory setting, including six RCTs. 
Surprisingly, 50% of the RCTs reported significant improvements in monitoring while
50% did not. A detailed review of each of the studies identified important aspects of
study quality, analysis and intervention design that help explain these conflicting results.
Higher quality studies were less likely to show significant improvements in 
monitoring with HIT interventions compared to lower quality studies. Studies with lower 
quality scores10, 15 used less rigorous study designs (such as pre–post intervention timing 
rather than RCT) and analytic approaches. These differences may explain some of the
differences in intervention efficacy across studies. Because most of the HIT intervention 
studies were introduced in clinical systems with multiple clinical sites, it is important to 
account for non-independence of outcomes within each site due to local practice
variations that can explain differences between different sites. Likewise, because
clinicians cared for multiple patients within a site, it is important to consider non-
independence of outcomes (i.e., lab testing) between patients of the same provider 
because differences in care delivery between providers can also affect outcomes. Our 
review found that studies that addressed clustering in their design and analysis were less
likely to show improvements in lab monitoring.11, 14 
We also found that all of the RCTs were conducted in one of two large integrated 
healthcare systems in the US. Study setting appears to be related to study results in two 
ways. First, both studies conducted outside of a large integrated health care system in the
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US were less rigorous pre–post intervention trials,10, 15 and each showed significant
improvements. Second, one of the integrated healthcare systems had high baseline rates
of monitoring,11, 14 and our review indicates that studies in sites with lower baseline rates
of monitoring reported greater improvements from HIT interventions compared to sites
with higher baseline monitoring rates.13, 15, 24 
Intervention design features may also explain the conflicting study results. Our 
review revealed that the 2 interventions that targeted pharmacists were effective 9, 13, 
while only 3 of 6 interventions targeting physicians were effective. 10, 15, 24 One study 
compared 3 arms, including an arm with electronic alerts to physicians, a second arm
with voice mail messages to patients, and a third with pharmacy team outreach to 
patients, and found that the physician alert arm was the least effective.24 Past evidence
suggests that changing physician behavior is challenging, and that passive approaches
(non-interruptive alerts) to such physicians may not be effective.50-52 It does not appear 
that the intrusiveness of the alert explains the difference in study findings, and this is not
inconsistent with several studies where nonintrusive reminders did not improve physician 
adherence to alert recommendations.53 
It is helpful to consider our results in the context of other literature on the
effectiveness of HIT interventions and their effects on prescribing errors and adverse
drug events.21, 32 Most reviews included a small number of studies, and many report that
the studies reviewed were of low quality. For example, a 2003 review reporting error-rate
improvement from clinical decision support-only interventions included seven studies, 
many of which were under-powered.21 Another review of HIT interventions to improve
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drug dosing, mostly in the inpatient setting, found that many studies were of low
quality.47, 48 None of these studies addressed laboratory monitoring. 
Variation in intervention effectiveness is also reported in other reviews of HIT
interventions. For example, one review of the effect of computerized physician order 
entry and clinical decision support on ADEs found that only half of the studies showed a
reduction in ADEs54, and another systematic review of CPOE and medical errors reported 
that while more than half of studies found significant reductions in ADEs the results
varied widely. Although the investigators concluded that CPOE can reduce prescribing 
errors, they noted, “Reporting quality and study quality was often insufficient to exclude
major sources of bias.”55 The findings of our review are similar, with a slight majority of
studies finding a positive impact of the interventions, but with variation in quality. As
with reviews, the number of studies addressing this issue is still limited.
There are several limitations to our review that should be noted. First, given the
relatively small number of studies identified, it is difficult to draw conclusions about the
overall impact of HIT intervention on rates of laboratory monitoring. By limiting our 
search to Medline English-language studies, we may have missed some non-US studies, 
but this allowed us to adequately review the study methodologies. Further, all studies
regarding anticoagulation were excluded because it was not possible to identify the
independent effect of interventions to improve lab monitoring (i.e., INR testing) from
dosing recommendations for warfarin. This limits the inferences we can make about HIT
interventions on lab monitoring overall. Second, the studies were conducted in a limited 
number of clinical settings: three of the studies were conducted at one site and two at a
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second site. Further, all but one of the studies were conducted in large managed care
organizations, limiting generalizability of the findings outside of these settings. Finally, 
differences in study design made it difficult to compare outcomes across studies. While
we were unable to use meta-analysis to pool the effect sizes, we did compare the effects
of the interventions across several studies on a single drug common to all studies, and did 
not find any consistent effect of HIT interventions on monitoring.
While the idea of using HIT to improve quality of care is not new,56 this goal has
not yet been achieved. Many questions still remain, as posed by Kuperman et al. in 2007:
“To what extent does alerting impact on clinician behavior and patient outcomes? What
is the optimal way to present alerts to prescribers? Which member of the health care
team—for example, physician, nurse, pharmacist, other—is the best recipient of any kind 
of alert?”8 These questions have yet to be answered. As more outpatient clinics adopt
electronic records and electronic prescribing, it will be increasingly important to know
the impact of decision support in this setting to support implementation of the most
effective interventions. This is particularly true with regard to laboratory monitoring, 
which is often a locus for preventable adverse effects.
While numerous reviews and studies have attempted to answer these questions, 
our systematic search identified more interventions in the inpatient setting than in the
ambulatory setting. Of the studies identified, concerns about study quality and design 
could not exclude sources of bias in the reported results. Future studies of laboratory
monitoring should better address patient and provider characteristics and account for 
fixed physician or clinical site effects by multilevel analysis. Studies can also better 
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clarify outcomes (i.e., improvements of test ordering versus test completion), and should 
also be expanded to include settings outside of the large integrated health care delivery 
systems.
While this systematic review found evidence suggesting information technology 
interventions may improve lab monitoring for high-risk prescribed medications
(exclusive of anticoagulants) in the ambulatory setting, the evidence is conflicting. Of the
well-considered, well-designed studies reviewed, there appears to be little improvement
of lab monitoring for high-risk medications with HIT interventions targeting physicians
only. However, five of eight studies found some positive effect, and this suggests that this
using HIT may be a promising avenue for improving laboratory monitoring. More
research is needed to determine how to maximize the full potential benefit of HIT to 
monitor high-risk medications and ultimately improve patient safety.
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CHAPTER III
 
HIGH-RISK MEDICATION MONITORING TESTS:
 
A MIXED-METHODS EXPLORATION OF COMPLETION
 
AND BARRIERS
 
A. Abstract
Objectives
To quantify physician ordering and patient completion of laboratory monitoring tests for 
high-risk medications in the ambulatory setting and to describe patient reasons for non-
adherence to physician test orders. We hypothesized that both physician and patient
factors would contribute to patients not receiving appropriate laboratory monitoring.
Design
Using a mixed-methods approach, we used a cross-sectional study to measure the
frequency of physician ordering and patient completion of laboratory tests for selected 
chronic medications (including cardiovascular medications [ACE inhibitors and ARBs, 
statins, digoxin, diuretics, fibrates, and niacin], anti-convulsants [phenytoin, valproic
acid, carbamazepine and phenobarbital], potassium supplements, and thyroid replacement
therapy) prescribed in a large multispecialty ambulatory group practice between January 
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1, 2008 and July 31, 2008. To elicit reasons for completing or not completing the ordered 
test, we additionally conducted qualitative interviews with a sample of patients who 
completed and those who failed to complete an ordered test.
Participants
Patients aged 18 and older in a large multispecialty group practice who were prescribed a
high-risk medication requiring laboratory monitoring, including 23 patients who 
participated in structured interviews.
Measurements
For a list of 14 medications and associated recommended laboratory monitoring tests, 
resulting in a list of 23 high-risk drug-test pairs, we quantified the proportion of tests
missed due to provider non-ordering compared to patient non-completion. From a series
of patient interviews, we explored reasons for not completing ordered laboratory tests.
Results
During the observation period, there were almost 50,000 prescriptions for the study 
medications, of which almost 43,000 were to chronic users. The unit of analysis was the
first prescription and first incidence of the recommended test—a drug-test pair—during 
the study pair. Test ordering and completion varied across drug-test pairs. Physician non-
ordering of recommended tests, ranged from 1% to over 50% across drug-test pairs;
patient non-completion of ordered tests ranged from 2% to almost 25%. Overall, 71% of
drug-test pair non-completion was due to lack of test ordering; 29% was the result of
patients not completing the test. In structured interviews, the reasons patients provided 
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for not completing lab tests were from two major domains: human factors, including 
cognitive reasons (e.g., they simply forgot) and competing demands; and systems issues, 
including transportation. Other logistical issues (e.g., long waiting times at the lab) were
not mentioned by patients as reasons for missing tests, nor were patient beliefs about the
tests or lack of understanding of the reasons for them.
Conclusions
While most missed opportunities for laboratory monitoring of high-risk medications in 
the ambulatory setting are attributable to lack of physician orders, patient non-adherence
contributed to under-testing. Interventions to improve laboratory monitoring should target
patients as well as physicians. Reminders to patients about due dates for ordered tests
could improve adherence.
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B. Background
Many prescription medications, including those commonly prescribed in the
outpatient setting, pose serious risks. Drug-induced injury is common in this setting.3, 57 
Failure to monitor high-risk medications has been shown to be a leading factor 
contributing to adverse drug events (ADEs).3 However, data about monitoring rates are
limited.
For adults treated in the ambulatory setting, initial drug dispensing occurs without
recommended laboratory monitoring in as many as 39% of cases.4 This is higher among 
older adults, where up to 58% of initial drug dispensings have been shown to occur 
without recommended lab monitoring.41 For maintenance therapy, rates of recommended 
follow-up testing are generally lower than for baseline monitoring.11 In one study focused 
on chronic medications, more than 40% of patients did not receive at least one of the tests
recommended for drug safety monitoring.42 Because many patients take multiple
medications and some medications have more than one recommended laboratory test, 
potential laboratory-monitoring errors affected up to 80% of patients in this study.
Overall completion necessarily represents a subset of the ordering. The
completion rate is therefore lower, yet reporting the completion rate alone conflates
physician behavior and patient behavior. While previous studies show that overall test
completion for monitoring high-risk medications is low,4, 12, 24 most studies do not
disentangle the independent contributions of lack of physician test ordering and 
incomplete patient adherence to lab test orders. Some studies report clinician ordering 
only,14, 15 while others report test completion rates only;10-12, 24, 58 none report patient
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adherence to ordered testing. This knowledge gap makes it difficult to determine whom
to target to improve laboratory monitoring.
In cases where tests are ordered but not completed, we have little information on 
the reason patients fail to complete the tests. It is possible that patient understanding of
the reason for testing may correlate with test completion. This has been found for 
warfarin, where patients’ knowledge about warfarin has been found to be a determinant
of anticoagulation control.59 Work on abandoned prescriptions has suggested that
patients’ relationships with physicians, wait times in the pharmacy, condition of the
testing facility, and co-payment costs are associated with increased abandonment,60 
factors that may be important in test completion as well. Forgetting is known to be a
common reason for missing appointments,61, 62 but it is not known what its role is in 
failing to complete laboratory tests.
To quantify physician ordering and patient completion of laboratory monitoring 
tests for high-risk medications in the ambulatory setting and to identify factors associated 
with completion, we conducted a mixed-methods study in a large multispecialty 
ambulatory group. We focused on medications commonly implicated in ADEs or those
with narrow therapeutic windows. To understand reasons for non-adherence to physician 
test orders, we also conducted interviews of patients prescribed one of these medications
who had missed recent monitoring tests.
The specific aims of this study were to determine: 1) the prevalence of completion 
of recommended laboratory tests to monitor high-risk medications; 2) the proportions of
incomplete testing attributable to lack of clinician test ordering and to patient non-
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adherence to ordered tests; and 3) what factors might be contributing to patient non-
adherence. We hypothesized that while incomplete ordering would be an important
factor, non-completion would have more influence on overall rates, and that patients
would identify many barriers to completion, including timing and access, as well as
limited understanding of the reasons for testing, that would not be measurable in the
electronic medical record (EMR).
C. Study Design and Sample
This study was conducted in a large multispecialty group practice that provides
most of the medical care for members of a closely associated, New England-based health 
plan. In 2010, the group practice employed 330 outpatient clinicians, including 250 
physicians, at 23 ambulatory clinic sites covering 30 specialties. The study population 
was derived from the Fallon Community Health Plan (FCHP) members who receive
medical care from Fallon Clinic (n=72,611 in 2008). The age and gender characteristics
of the study population are generally similar to those of the general population of the
United States, though the Fallon Clinic patients are generally older.
The practice uses the EpicCare Ambulatory electronic medical record (EMR) 
system (Epic, Verona, WI, Spring 2007 IU3 at the time of the study) and provides
medical care to approximately 180,000 individuals. The study population was derived 
from the health plan membership aged 18 years and older who received care at the
multispecialty group practice. The age and gender characteristics of the study population 
are similar to those of the general population of the United States, and include 36% who 
are aged 65 years and older (Table 3.1). While the health plan does not systematically 
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measure race, the plan’s market research indicates a patient racial mix consistent with the
plan’s catchment area, which includes whites 79%, Hispanics 12%, African Americans
5%, and other races 4%.
Table 3.1: Age and Gender Characteristics of Study Population vs. U.S. Population
Aged 18 and Older
Target Study Population United States
(n=72,611) (n=210,430,341)*
Age Group Male Female Total Male Female Total
18 – 44 15% 17% 32% 26% 26% 53%
45 – 54 9% 9% 18% 9% 9% 18%
55 – 64 7% 7% 14% 6% 6% 12%
65 – 74 6% 8% 15% 4% 5% 9%
75 – 84 6% 9% 15% 2% 4% 6%
85 + 2% 4% 6% 1% 2% 2%
Total 46% 54% 100% 48% 52% 100%
*Aged 18 years or older, 2000 census63 
For the quantitative portion of this study, patients were included if they received 
care from the multispecialty group, were aged 18 or older, and had insurance coverage
from the associated health plan between January 1, 2007 and July 31, 2008. Patients were
included only if continuously enrolled during the observation period and not residing in a
long-term care facility.
A subset of these patients was interviewed for the qualitative study. Data about
medication exposure were derived from the prescription drug claims of the health plan. 
Data about the date of laboratory test ordering and completion were obtained from the
EMR. At the time of the study, the EMR did not have clinical reminders to obtain 
laboratory testing if patients were taking particular medications or had relevant medical
conditions. 
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Selection of drugs and monitoring tests
The medications included in this study were selected from a list of ‘high-risk’ 
medications with recommended laboratory monitoring tests developed for a clinical
decision support system that was intended to be embedded in the EMR by our research 
group, working with the practice. The development process included a multi-step review
process by a national advisory committee as well as local expert review of a
comprehensive list of medications as described in detail elsewhere.16 For that study, 
medications were considered ‘high-risk’ and candidates for inclusion in the clinical
decision support system included those commonly implicated in ADEs in the ambulatory 
setting,3 adverse events leading to emergency department visits,64 drugs previously 
determined to be associated with low rates of recommended monitoring,4, 24 drugs with 
monitoring recommended in national quality guidelines,65 and drugs with laboratory-
monitoring-associated black box warnings (BBW).66 The list of indicated laboratory 
monitoring tests for each drug was developed in close conjunction with two research 
pharmacists who reviewed the literature and product labeling to determine the
appropriate test frequency for each drug-test pair. The final guideline list is listed in 
Chapter IV and includes 34 drugs or drug classes, some with multiple recommended 
tests, for a total of 60 drug-test pairs, of which 16 (27%) have BBWs. For the purpose of
the studies described in this dissertation, we use the following terminology: any drug 
from the guidelines list is referred to as a high-risk medication, given the potential risk 
associated with these drugs. A subset we specifically refer to as a BBW drug-test 
combination, if the medication has a black box warning that is associated with a specific
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laboratory test. Warfarin was not included in the analyses for this dissertation because it
is primarily managed by a specialized anticoagulation clinic in most health care systems, 
including our system.
This chapter describes a study that included a subset of these high-risk 
medications: those often prescribed in the outpatient setting for common chronic
conditions that require monitoring, specifically cardiovascular medications (ACE
inhibitors and ARBs, statins, digoxin, diuretics, fibrates, and niacin]); anti-convulsants
(phenytoin, valproic acid, carbamazepine and phenobarbital); potassium supplements;
and thyroid replacement therapy (Table 3.2). 
Table 3.2: Drugs with Recommended Tests and Test Frequencies
Drug Test Minimum
recommended
testing frequency
ACE AND ARBS BMP Yearly
AMIODARONE AST/ALT Twice yearly
TSH Twice yearly
ALL DIURETICS BMP or Cr&K Yearly
DIGOXIN Cr&K Yearly
FENOFIBRATE AST/ALT Yearly
CBC Yearly
GEMFIBROZIL AST/ALT Yearly
NIACIN AST/ALT Yearly
STATIN AST/ALT Yearly
POTASSIUM SUPPLEMENT K Yearly
THYROID SUPPLEMENT TSH Yearly
CARBAMAZEPINE AST/ALT Yearly
CBC Yearly
CARBAMAZEPINE Yearly
PHENOBARBITAL AST/ALT Yearly
CBC Yearly
PHENOBARB Yearly
PHENYTOIN AST/ALT Yearly
PHENYTOIN Yearly
VALPROIC ACID AST/ALT Yearly
CBC Yearly
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VALPROIC ACID Yearly
Abbreviations: ACE inhibitors = angiotensin-converting enzyme inhibitors; ARBs = angiotensin receptor
blockers; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BMP = basic metabolic
panel; CBC = complete blood count; Cr = creatinine; K = potassium; TSH = thyroid stimulating hormone:
i. Quantitative Analysis
We used drug dispensing claims to identify the first dispensing of one of the high-
risk medications of interest prescribed after January 1, 2008 for an ambulatory patient. 
Chronic drug use was defined as a dispensing with evidence of another drug dispensing 
in the 6 months prior to that date. Each medication (or drug class) had one or more
recommended test. Only one instance of each drug-test pair was included for analysis. 
Clinician test ordering was defined as having occurred if there was at least one
recommended test for the drug-test pair ordered up to 365 days before the index 
dispensing in 2008 through 14 days after the dispensing if the test was indicated annually 
(or 180 days before to 14 days after index dispensing if the test was indicated every 6 
months). Patient test completion for each ordered test was then determined by matching 
the test order with test results based on a unique order identifier. Tests ordered outside of
the group practice (e.g., in the hospital or other clinician practice) were not captured. For 
each drug-laboratory test combination, the proportion of ordered and completed 
recommended tests was determined for all index dispensings in the observation period. 
Analyses were conducted in SAS 9.2 (SAS Institute, Cary, NC, USA). This study was
approved by the institutional review boards of the University of Massachusetts Medical
School and the multispecialty group practice.
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ii. Qualitative Analysis
To better understand patient non-adherence to lab testing as measured in the
quantitative analysis, we undertook a qualitative approach to identify patient factors that
might contribute to missing laboratory tests. The open-ended semi-structured interview
approach allows broader identification of issues, limits the impact of researcher bias in 
exploring patient reasons for non-attendance, and is able to solicit information not
available in the electronic record.67 
Qualitative Interview Guide Development
Using a semi-structured interview format, we examined why patients themselves
missed laboratory tests and what barriers to completion they thought existed for both 
themselves and others. Questions were developed based on the literature29, 61, 62, 67-73 and 
were designed to elicit personal experiences of missed laboratory tests and understanding 
of the reason for them (Table 3.3). Patients were also presented with educational material
to be used for a potential, future intervention and were asked for feedback. Two pilot
interviews were conducted to provide training for the interviewer and to test the protocol, 
leading to further refining of the questions.
Table 3.3: Topics Covered in Qualitative Interviews
Lab tests in past year
For what?
Understanding of reason? Is it important to you to understand why?
Did your doctor explain why? Explain the procedure?
Do you remember missing a test? Why did that happen?
Experience of lab test (convenience, treatment at lab, time, concerns)
Relationship with doctor
Communication, specialty
Reminders
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From clinic? What would be most helpful?
Your own system?
Specific questions
Transportation? Cost? Scheduling? Missed because of stopping a med?
What makes it easier? Harder?
Speculation about others’ reasons for missing a test
Recruitment, Data Collection, and Analysis
We used a purposive sampling approach to select patients for qualitative
interviews in order to capture patients who did complete (‘shows’) and did not complete
(‘no-shows’) a laboratory test ordered for a subset of the medications analyzed in the
quantitative portion (ACE inhibitors and ARBs, statins, phenytoin, valproic acid, digoxin, 
and thyroid replacement therapy). This sampling strategy aimed to include both men and 
women and a representation of older adults (age > 65).
To identify potential study candidates, a member of the research team reviewed a
list of patients who missed a scheduled laboratory test between July 2008 and October 
2010. Missed tests were identified by reviewing the completion date for the test and 
determining whether the date had passed without a test registered in the system. We also 
identified patients who completed a laboratory test in the same time period using the
same approach.
To determine study eligibility, we reviewed the EMR for patients having a
prescription for one of the study medications, having an order for a related lab test, 
receiving care at the multispecialty group practice, and being aged 18 or older. Eligible
patients were contacted via telephone by a research nurse, assessed for interest and ability 
in participating in an English-language interview, and invited to participate in the study 
(Figure 3.1). Patients contacted were offered in-person interviews in our research office
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as well as the option of participating in a telephone interview if there was an indication of
transportation difficulties in the medical record or if the patient suggested that travel
would limit participation.
Patients with an indication of inability to provide informed consent, including 
those with a history of cognitive impairment, dementia, or severe thought or mood 
disorders, were not contacted.
Figure 3.1: Qualitative Interview Recruitment 
102 patients received study invitation letters
36 patients refused on telephone follow-up, 35 not reached
31 patients contacted by RA
8 refused for various reasons
16 ‘no-show’ patients
7 additional patients who did show
= 23 interviews
Each participant was sent a consent form and a description of the study and was
then contacted by a research assistant to schedule the interview. The research assistant
was blinded to the test completion status of the patient and to the patient’s medical
history. Interviews took about 45 minutes and patients were given a $25 stipend. All 
interviews were recorded and transcribed.
Using a grounded theory approach,74 two researchers developed codes based on 
four randomly selected transcripts and then met to review and reconcile differences in the
codes. Grounded theory is a qualitative research approach developed in the late 1960s in 
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order to study data on caring for dying patients.74 The method aims to generate theories 
from the data by researchers reviewing documents or transcripts and then coding each 
section (constant comparative data analysis). Codes are then compared and refined and 
used to identify themes. Sample size is determined using ‘theoretical saturation.’75 
Quantitative approaches can also be applied once the data are coded.
The codebook developed by the two researchers was then used to code the
remaining transcripts. Interviews were conducted until theme saturation was achieved, 
meaning we reached a point in the interviews where we no longer heard new ideas from
participants.76-78 Prior studies suggest that saturation can be reached with as few as 12 
interviews.76 We interviewed 16 patients who did not complete ordered tests. We
additionally interviewed 7 patients who did complete ordered tests, and their comments
were very similar to those who had missed at least one test. We completed 23 interviews
and terminated data collection. 
Analyses were conducted using NVivo qualitative data analysis software (QSR 
International Pty Ltd. Version 8, 2008, Victoria, Australia).
D. Results
i. Quantitative Study
Table 3.4 shows the number of prescriptions and overall completion rates (test
ordered by provider and completed by patient) for chronic prescriptions of study drugs. 
Completion rates varied from 37.9% (Valproic Acid-AST) to 96.8% (Niacin-AST), with 
more similar completion rates within a specific medication and varying rates of the same
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test (for example, AST), suggesting the differences were due to the medications and 
perhaps their indication. For example, the psychiatric medications had lower completion 
rates than others in this data set.
Table 3.4: Overall Completion of Indicated Tests for Chronic Users of Study 
Medications
Drug (Test) # chronic prescriptions for this
medication (# drug-test pairs)
% of indicated
tests completed
ACE AND ARBS (BMP) 8765 88.3%
AMIODARONE (AST) 79 59.5%
AMIODARONE (TSH) 79 48.1%
ALL DIURETICS (BMP or Cr&K) 9784 88.5%
DIGOXIN (Cr&K) 1015 90.2%
FENOFIBRATE (AST) 190 86.3%
FENOFIBRATE (CBC) 190 70.0%
GEMFIBROZIL (AST) 697 81.3%
NIACIN (AST) 95 96.8%
STATIN (AST) 13351 84.0%
POTASSIUM SUPPLEMENT (K) 1610 90.4%
THYROID SUPPLEMENT (TSH) 4660 70.0%
CARBAMAZEPINE (AST) 193 57.5%
CARBAMAZEPINE (CBC) 193 72.5%
CARBAMAZEPINE (CARBAMAZEPINE) 193 57.0%
PHENOBARBITAL (AST) 52 46.2%
PHENOBARBITAL (CBC) 52 69.2%
PHENOBARBITAL (PHENOBARB) 52 53.8%
PHENYTOIN (AST) 313 46.3%
PHENYTOIN (PHENYTOIN) 313 75.7%
VALPROIC ACID (AST) 248 37.9%
VALPROIC ACID (CBC) 248 62.1%
VALPROIC ACID (VALPROIC ACID) 248 44.8%
Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor
blockers; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMP, basic metabolic panel;
CBC, complete blood count; Cr, creatinine; K, potassium; TSH, thyroid stimulating hormone.
Figures 3.2 and 3.3 show the rates of completion and reasons for non-completion 
for included medications. While the cardiovascular and potassium and thyroid 
replacement therapy medication-test pairs generally had completion rates of 60-80% rates
were lower for the anti-convulsant medications. Overall, provider non-ordering was
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responsible for the larger portion of the non-completion for these pairs (Figure 3.3). 
Provider non-ordering rates varied from 1.1% (Niacin–AST drug-test pair) to 51.6% 
(Valproic Acid–Valproic Acid level drug-test pair), while patient non-completion varied 
from 2.13% (Niacin–AST) to 24.19% (Valproic Acid–AST).
Figure 3.2: Completion and Non-Completion of Tests
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Figure 3.3: Physician Test Non-Ordering Compared to Patient Non-Adherence 
 
ii. Qualitative Results 
 Interviewed patients had a mean age of 63, were mostly female, and were all 
white (Table 3.5). Most were selected because they were taking an ACE inhibitors or a 
statin. Several themes regarding laboratory monitoring emerged during the qualitative 
data analysis, including human factors and system factors that contribute to lab 
attendance. 
Table 3.5: Interviewed Patient Characteristics 
Patient Characteristics Total Sample 
N=23 
No-show Patient 
N=16 
Show Patient 
N=7 
Patient Age    
 Mean (Range, SD) 63.1 (34-89, 13.6) 60.3 (34-89, 15) 69.57 (62-80, 6.2) 
Gender    
 Female 17 (73.9%) 14 (87.5%) 3 (2.9%) 
 Male 6 (26.1%) 2 (12.5%) 4 (57.1%) 
Interview format    
 In-person 17 (73.9%) 12 (75%) 5 (71.4%) 
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 Telephone 6 (26.1%) 4 (25%) 2 (28.6%) 
Medication    
 ACE Inhibitor 7 (30.4%) 6 (37.5%) 1 (14.3%) 
 ARB 1 (4.3%) 1 (6.3%) 0 (0%) 
 Phenytoin 3 (13%) 2 (12.5%) 1 (14.3%) 
 Statin 10 (43.5%) 6 (37.5%) 4 (57.1%) 
 Thyroid 2 (8.7%) 1 (6.3%) 1 (13.3%) 
Highest Degree    
 Some high school 1 (4.3%) 1 (6.3%) 0 (5) 
 High school graduate 9 (39.1%) 6 (37.5%) 3 (42.9%) 
 GED 1 (4.3%) 1 (6.3%) 0 (0%) 
 Some college 5 (21.7%) 4 (25%) 1 (14.3%) 
 Associates degree 3 (13%) 2 (12.5%) 1 (14.3%) 
 Bachelors degree 4 (17.4%) 2 (12.5%) 2 (28.6%) 
Abbreviations: SD, standard deviation; ACE, Angiotensin-Converting Enzyme; ARB, Angiotensin II 
Receptor Blockers; GED, General Education Diploma. 
Factors That Affect Completion 
 When asked why they had missed lab tests, 7 of 16 patients said they simply 
forgot (Figure 3.4). While many patients (11) said they used a calendar as their system to 
remember to get tests, including the majority of the patients who completed their tests (4 
‘show’ patients), others said they had no system at all (3 ‘no-show’ patients). 
Forgetting 
 Forgetting was the most frequent cause of a missed lab test. The interviewer asked 
each patient if he or she recalled missing a lab test. While some patients denied missing a 
lab test, most patients acknowledged missing a lab test and cited forgetting as the reason. 
When explaining why she forgot, one patient noted that it was probably because the test 
was due at a time without a visit to the provider: “[The physician] does [the lab tests] not 
just yearly, but in between sometimes.” A number of patients could not indicate a reason 
why they could not remember to complete the test. 
Competing demands 
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Three patients identified competing demands that led them to delay or miss their 
lab tests. They understood the importance of the test but simply had extenuating 
circumstances or other factors that led these patients to postpone test completion. As one
patient said, “I missed that one [test], but I was having a lot of problems with the family 
and things were going on and I just couldn’t be bothered. But that was my own fault; it
was nothing to do with the procedure.”
Transportation
One patient identified transportation barriers, stemming from a disability, as the
reason for the missed test. A second patient indicated challenges with finding 
transportation, but noted that she had never failed to complete an order because of such 
problems.
Other concerns
A majority of participants indicated that they did not have concerns about
undergoing a lab test. In response to a question about lab concerns, a few patients noted 
that they disliked needles, but they clarified that the process has become routine and their 
needle aversion does not affect attendance. As one patient said, “Well, who likes
[needles]?…I don’t love them, but…you’ve got to do what you’ve got to do.” However, 
one patient did note that a dislike of needles influenced him to delay a lab test past the
desired completion date.
Access and logistics
Most participants did not indicate any problems with reaching a lab facility to 
complete their test orders. Patients noted that the option to choose from several locations
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and lack of appointments made the process easier. “Easy, you can go any time…you’re
right in and out.” Many praised the convenient locations, the short waits, and the friendly 
and competent staff.
Frequency of lab tests
‘No-show’ patients reported a greater frequency of ordered lab tests per year than 
the ‘show’ patients. Many patients with a missed test said that they tended to have an 
order for blood work every three months. In contrast, of the ‘show’ patients, those who 
had not missed a test, only one reported having to perform a blood test more than two 
times per year. 
Factors That Could Improve Completion
Reminders
Most patients, including those who missed a lab test, said they had some sort of
personal reminder system, with a paper calendar as the most popular tool. Some patients
with an incomplete test did not have a reminder system, while all patients who had 
completed all tests used some type of personal reminder. Some participants noted that
they used the health practice group’s online health portal to check for upcoming 
appointments. “It helps me set up my medications, set up my appointments, look at my 
appointments, missed appointments…and get the results.”
Some patients indicated that the clinic did not send reminders for lab tests. When 
asked, many agreed that they received no reminders about lab tests, but neither did they 
express concern about this. When prompted regarding what type of reminder the clinic
should send for lab tests, most participants expressed preference for a telephone call. “A
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call is the best thing…just like when they call to remind you that you have an 
appointment [with a provider].” A few patients did not have a preference for reminder 
type or thought a reminder would be unnecessary.
Comprehension and education
Many patients were able to explain the reason for the lab test. Patients most
commonly spoke about tests as necessary for preventing side effects, adjusting 
medication dose, and checking organ function. Some were very specific about the
connection between the test and their medications: “Every blood test is critical… 
especially the [phenytoin] levels, because they have to keep them at that therapeutic level
rather than the toxic.” Others spoke in more vague terms about the reason for testing, as
in the following answer to the question of why a test was being conducted: “I’m a
diabetic and they have to read the range of my something from zero to seven, or whatever 
it is. I don’t know what it is they do, but that’s why I go.”
A number of patients, both those with and without an incomplete lab test, said that
it was important to understand the purpose of the test. One explained the purpose as, 
“…To understand my medication levels, and when my levels go up and down to readjust
things—it’s very important for me if I want to be healthy.” No participants indicated that
they missed a lab test due to not knowing its purpose. Furthermore, patients generally 
stated they understood the reasons for their tests and were satisfied with the explanations
from their physicians.
Patients also gave feedback about potential educational messages. While some
liked the idea of a message as a reminder, overall, patients did not feel the messages
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would add to their understanding, given the information they already receive. As one
patient said, “I think I would want one [message] just in case something happened and I 
have this to fall back on. But usually if I go on a new medication or something, she
[physician] tells me up front what can happen, and if I’m going to need additional lab 
work. And then if I get the medication at the pharmacy, it tells me what to look for.”
They also generally thought that they already understood the information presented, 
though it might help others.
Figure 3.4: Reasons Given for Missed Tests
E. Discussion
This mixed-methods study adds to the literature on laboratory monitoring for 
high-risk medications by quantifying the relative contributions of physician test ordering 
behavior from patient adherence behavior to overall under-monitoring, and by directly 
soliciting patient perspective about how to improve test adherence. In our setting, we
found that provider non-testing was greater than patient non-adherence. Further, 
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qualitative interviews suggested that patient reminders might help improve test
completion, but improving patient understanding about testing probably would not.
Prior literature either evaluates physician test ordering14, 15 or patient test
completion;10, 11 however, rarely are both reported.9, 16 Our study found slightly higher 
rates of physician test ordering than in previous studies,14, 15 though it is difficult to 
compare given the different tests recommended, the lack of detail in publications, and the
lack of a look-back period (for certain tests completed before the prescription, obviating 
the need to test after) in some studies.14 
Patient non-adherence once a test was ordered was lower, ranging up to 24.2% for 
AST test completion in patients taking valproic acid. These completion rates are in fact
high; other literature about patient non-adherence,4 and our completion data for patients
on new medications and for patients with less common medications (not reported here), 
show even higher rates of non-completion.
Human factors connected to attendance were for the large part cognitive. Patients
identified forgetting as the dominant reason for missing tests, even as they demonstrated 
understanding of the reasons for the tests and denied other barriers to attendance. They 
did also identify a number of concerns, when prompted, like fear of needles, but these
concerns did not seem to be barriers to test completion.
Health systems factors have also been identified as reasons patients miss
appointments,67, 73 but the patients in this study did not identify major barriers either to 
access or with logistics for attendance.
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i. Forgetting and Reminders
The current system may contribute to forgetting, because patients are told to get
tests within a certain time frame but not at a specific time. This flexibility generally 
works—overall completion rates are relatively high—but without a concrete
appointment, human factors make it easy to forget to complete a lab test order. Our multi-
specialty practice is responding to these findings with interventions to address the
reminder issue, including phone calls prior to lab test deadlines.
However, addressing patient compliance via reminders and scheduling changes
will never lead to a 100% completion rate, as shown through the quantitative data, 
without considering the physician factors that contribute to ordering as well. One study 
interviewing physicians about lack of ordering drug monitoring tests found that important
factors include lack of clarity about which provider was responsible for ordering a test
and lack of certainty regarding the necessity of monitoring as well as lack of reminders to 
physicians.26 These problems should also be targets for interventions.
There is not a single explanation for incomplete laboratory monitoring. 
Interventions to improve monitoring will have to target both ordering and completion, 
and data should report the two rates separately, which is currently rarely done.23 Part of
this is due to a lack of electronic record usage, which is required for accurate ordering 
rates (most studies report completion rates, as determined from claims data, which is
easier to access but may be less accurate).79 
One strength of our study is the computerized system from which we derived our 
quantitative finds. While prescriptions are often trackable using claims data, it is very 
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difficult to track test orders without an electronic medical record. Furthermore, because
this study was conducted in a single system with electronic ordering and claims data, plus
information about enrollees and providers, we were able to conduct analyses that might
be hard to do elsewhere. We were able to then identify and conduct interviews with 
patients whom we knew had missed a test. This allowed us to target our study to the
patients with whom we hope to effectively intervene.
Limitations of our study should be noted. As above, patients receiving care from
the multi-specialty group practice are representative of the population of central
Massachusetts. Although the practice is similar to many similar healthcare provider 
groups across the US, it is different in that it is an integrated health care system and it is
one of the early providers to have full implementation of electronic medical records and 
computerized physician order entry (CPOE). Second, laboratory tests may have been 
ordered for another reason (i.e., not for high-risk medication monitoring), so that we may 
have overestimated the prevalence of recommended testing. At the same time, we may 
have missed monitoring that was done at a hospital. Third, for the quantitative portion, 
we were unable to confirm patient adherence to drugs and were unable to identify 
patients who did not complete tests because they were no longer using the medication. 
Fourth, for many drugs, further study is necessary to determine whether laboratory test
monitoring improves health outcomes, and these differing levels of evidence may have
affected provider choice in choosing what tests to order. This issue is discussed further in 
Chapter IV. Fifth, while we interviewed patients about their reasons for missing tests, we
did not speak to physicians about their reasons for failing to order tests. Lastly, the
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patients who were interviewed for the qualitative piece may not be representative of the
whole population, given that the same barriers that prevent completing testing may also 
impede appearing for an interview. We attempted to overcome that issue with telephone
interviews, but we cannot rule out that we missed patients who had more significant
barriers to both testing and interviewing.
ii. Conclusion
Our study demonstrates higher rates of completion than some similar studies, but
still low rates overall given the importance of laboratory monitoring. However, our 
results further suggest that systems factors like transportation, wait time, or co-payment
were not major reasons for test non-completion. Similarly, patent understanding did not
seem to be a large factor in the decision to complete a test. Rather, patients reported that
they simply did not remember to get tests, which unlike appointments were not set for 
specific times and dates, and that the reminder systems that they did use were unreliable.
This work furthers the evidence for the potential for improvement in monitoring 
rates and the potential benefit of the EMR in improving quality of care. As patients miss
appointments because of forgetting, reminders need to be implemented, but they will only 
be successful if done in a way that patients will receive them. More than half of the
interviewed patients were amenable to phone reminders. While many patients did not use
the health system’s patient portal at all, those who did found it to be a useful way to find 
out more about lab tests and get reminders regarding deadlines, thus suggesting it the
portal would be effective for improving testing among a certain population.
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As EMRs become more prevalent, researchers will be better able to separate
provider behavior and patient behavior. This will allow better targeting of interventions
to improve health care quality. At the same time, much behavior is driven by human 
factors. Everyone, provider or patient, is prone to forgetting, and without a reminder at
the right time, we may not be able to affect human behavior.
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CHAPTER IV
 
FACTORS ASSOCIATED WITH ORDERING
 
LABORATORY MONITORING OF HIGH-RISK 

MEDICATIONS
 
A. Abstract
Purpose
To determine physician factors that are correlated with ordering of recommended 
laboratory monitoring tests for high-risk medications after adjustment for patient
characteristics. We hypothesized that providers with less experience with a specific drug, 
specialty training, weaker testing recommendations, and healthier patients would be
associated with lower ordering laboratory tests for study medications.
Design, Participants, Measures, and Data Analysis
Cross-sectional analysis of the administrative claims and electronic medical records of
patients prescribed a high-risk medication requiring laboratory monitoring in a large
multispecialty group practice between January 1, 2008 and December 31, 2008. The
outcome is a physician order for each recommended laboratory test for each prescribed 
medication. Key predictor variables are physician characteristics, including age, gender, 
specialty training, years since completing training, and prescribing volume. Potential
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confounders include patient characteristics such as age, gender, comorbidity burden, 
whether the medication requiring monitoring is new or chronic, and drug-test 
characteristics such as inclusion in black box warnings and consensus or evidence-based 
guidelines. We used multivariable logistic regression to identify the independent
association of physician and patient characteristics with ordering of laboratory tests to 
monitor medications after adjustment for potential confounders, taking into account
clustering of drugs within patients and patients within providers.
Results
Physician orders for laboratory testing varied across drug-test pairs and ranged from 9% 
(Primidone–Phenobarbital level) to 97% (Azathioprine–CBC) with 50% of drug-test 
pairs in the 85-91% ordered range. Failure to order a test was associated with lower 
provider prescribing volume for study drugs, and whether the physician was a specialist
(primary care providers were more likely to order tests than specialists). Additional
factors included lower patient comorbidity burden and younger patient age were less
likely to have tests ordered. Drug-test combinations with black box warnings were more
likely to have appropriate tests ordered.
Conclusions
This study identifies factors associated with ordering of laboratory monitoring of high-
risk medications. Interventions targeting providers should be addressed at those
subgroups with the greatest potential for improvement: providers with lower frequencies
of prescribing, and healthier and younger patients. Drug-test combinations with black box 
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warnings have higher ordering rates, suggesting some effectiveness of warnings to 
providers, but many medications without such warnings also have evidence of harm, even 
if not as well-established, thus efforts to improve testing are necessary for all medications
shown to be high-risk.
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B. Background
Little is known about provider factors that contribute to ordering recommended 
laboratory monitoring. Beginning with the Institute of Medicine’s seminal report, “To Err 
is Human,”2 on the 44,000 to 98,000 deaths caused each year by medical errors, efforts
have been underway to improve patient safety and reduce the incidence of medical errors
in the United States. Errors in prescribing and monitoring medications constitute a major 
portion of these medical errors.3 
For preventable adverse drug events (ADEs) in the ambulatory setting, 
recommendations have targeted prescribing and monitoring errors,5 based on studies
identifying inadequate monitoring as the most common cause of preventable ADEs
among older adults, occurring in 60.8% of these events (followed by prescribing errors
and errors involving patient adherence).3 In the ambulatory setting, this has been shown 
to lead to hospitalizations and significant morbidity.11 
Medication monitoring refers to the need to monitor symptoms or lab results of
patients on specific medications to prevent toxicity or to monitor efficacy. For narrow
therapeutic window medications such as phenobarbital, serum drug levels are monitored 
to reduce risk of toxicity. For other medications, monitoring evaluates the physiologic
effect of medications. For example, angiotensin-converting enzyme (ACE) inhibitors can 
raise potassium and creatinine levels. And for some drugs, such as aminoglycoside
antibiotics or lithium, monitoring involves measuring both drug levels and physiologic
effects.8 
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One major challenge to appropriate laboratory monitoring by health care
providers is the lack of national guidelines and lack of expert agreement on appropriate
monitoring standards.80 However, even when guidelines are introduced, monitoring does
not meaningfully improve.81 And when recommendations do exist, whether from expert
guidelines or product inserts, they are not routinely followed.11 
Therefore, we conducted this study to identify provider characteristics associated 
with decreased ordering of recommended laboratory tests for high-risk medications in the
ambulatory setting, taking into account patient factors and whether drug-test 
recommendations were included in black box warnings (BBW) or clinical guidelines. 
We also included physician volume, as volume has been shown to correlate with 
better outcomes in other settings, such as surgery, where post-operative mortality is
correlated with higher surgeon and hospital volume.82-84 Providers with high frequency of
prescribing a given medication or those with more patients in their panels may be more
familiar with testing guidelines or may have seen potential adverse outcomes more often 
than less familiar prescribers, but this has not been studied with regards to monitoring. 
Similarly, specialty has been shown to be associated with clinical behavior in providers, 
with specialists often offering more care if not better outcomes,85-87 but this factor has not
been studied for laboratory monitoring guideline adherence.
The specific aims were to identify factors associated with provider ordering of
laboratory monitoring, including age, gender, specialty training, and years in practice for 
providers and age, gender, comorbidities, and new versus chronic user status for patients, 
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in adjusted and unadjusted models, as well as to stratify by evidence level for the testing 
and to compare the factors associated with ordering in each of these subgroups.
C. Methods
i. Study Design and Setting
This study was conducted within the Fallon Clinic, a large multispecialty group 
practice closely aligned with the Fallon Community Health Plan, a non-profit, Central
Massachusetts-based integrated health care delivery system, as described in Chapter III. 
The practice uses the EpicCare Ambulatory electronic medical record (EMR) system
(Epic, Verona, WI, Spring 2007 IU3 at the time of the study).
For this analysis, we included patients if they received care from the
multispecialty group practice, were 18 years or older, and had insurance coverage from
the health plan between January 1, 2007, and December 31, 2008. Patients had to be
continuously enrolled during the observation period and not residing in a long-term care
facility.
ii. Selection of Study Medications
The medications included in this study, as in Chapter III, were based on a list of
high-risk medications with recommended laboratory monitoring tests developed for a
clinical decision support system that was intended to be embedded in the EMR. The
development process included a multi-step review process by a national advisory 
committee as well as local experts review of a comprehensive list of high-risk
medications as described in detail elsewhere.16 Medications reviewed included those
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commonly implicated in ADEs in the ambulatory setting,3 adverse events leading to 
emergency department visits,64 drugs previously determined to be associated with low
rates of recommended monitoring,4, 24 drugs with monitoring recommended in national
quality guidelines,65 and drugs with laboratory-monitoring-associated BBWs.66 The list
of indicated laboratory monitoring tests for each drug was developed in close conjunction
with two research pharmacists who reviewed the literature and product labeling to 
determine the appropriate test frequency for each drug (Table 4.1).
Table 4.1: Study Medications and Recommended Tests
Persons prescribed the following high-risk medications (or classes) during 2008 were
included in the analysis.
DRUG TEST
ACE/ARB BMP
ALLOPURINOL CREATININE
AMIODARONE AST or ALT
TSH
AZATHIOPRINE AST or ALT
CBC
AZOLE ANTIFUNGAL AST or ALT
CARBAMAZEPINE AST or ALT
CARBAMAZEPINE
CBC
COLCHICINE CBC
CREATININE
CYCLOSPORINE AST or ALT
CREATININE
CYCLOSPORINE
DIGOXIN CREATININE
DIGOXIN
POTASSIUM
DIURETIC-LOOP BMP or K+Cr
DIURETIC-NOT-K-SPARING BMP or K+Cr
DIURETIC-POTASSIUM SPARING BMP or K+Cr
DIURETIC-THIAZIDE BMP or K+Cr
FENOFIBRATE AST or ALT
CBC
GEMFIBROZIL AST or ALT
ISONIAZID AST or ALT
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LITHIUM CBC
CREATININE
LITHIUM
TSH
METFORMIN CREATININE
METHOTREXATE AST or ALT
CBC
CREATININE
METHYLDOPA AST or ALT
CBC
NEFAZODONE AST or ALT
NIACIN AST or ALT
PHENOBARBITAL AST or ALT
CBC
PHENOBARBITAL
PHENYTOIN AST or ALT
PHENYTOIN
POTASSIUM POTASSIUM
PRIMIDONE CBC
PHENOBARBITAL
PRIMIDONE
QUINIDINE AST or ALT
CREATININE
POTASSIUM
QUINIDINE
RIFAMPIN AST or ALT
STATIN AST or ALT
TERBINAFINE AST or ALT
THEOPHYLLINE THEOPHYLLINE
THIAZOLIDINEDIONE AST or ALT
THYROID REPLACEMENT TSH
VALPROATE SODIUM AST or ALT
CBC
VALPROIC ACID
Abbreviations: ACE/ARB, ACE, Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor
Blockers; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMP, basic metabolic panel;
Cr, creatinine; K, potassium; TSH, thyroid stimulating hormone.
* Test completion for a new dispensing defined as occurred if there was at least one associated monitoring 
test ordered 180 days before to 14 days after dispensing, and for chronic dispensing as occurred if there was
at least one recommended test for the drug-test pair up to 365 days before or 14 days after the index
dispensing in 2008 (or 180 days before to 14 days after index dispensing if test was indicated every 6
months).
† Baseline serum drug level for new dispensings measured from date of index dispensing to up to 14 days
after index dispensing.
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iii. Medication Exposure
Data about medication exposure were derived from the prescription drug claims
of the health plan, while data about laboratory test orders were derived from the
multispecialty group practice electronic medical record. Use of claims data for 
medication exposure allowed for the measurement of medications actually filled at the
pharmacy, avoiding possible exposure misclassification by using EMR prescribing data
that may include prescriptions that were never filled or taken. In addition, the EMR 
includes “historical medications” which reflect over-the-counter medications and 
medications from outside providers but are inconsistently recorded across patients and 
providers. These medications are not included in the claims data and thus not included in 
this study, again meaning the possibility of not accounting for medications a patient is
taking but also decreasing the risk of erroneously considering a patient to be taking a
medication and thus underestimating appropriate testing.
In cases where a patient had more than one new start of the same drug during the
study time frame (no refills or prescriptions for 180 days and then a new prescription), we
used the first prescription for that drug only.
iv. Provider Factors
Provider data were collected from an internal provider demographic database
containing demographic information for past and present providers employed by the
multi-specialty practice. To maximize the dataset, we also included outside providers for 
whom we had specialty and gender. For many prescriptions, we did not have any 
individual provider information (the prescriber code was a generic code, specific to site
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but not to provider), and they were therefore excluded from analysis for provider 
characteristics with regard to ordering rates. These providers accounted for less than 15% 
of the number of providers matched to prescriptions in the dataset. Once exclusion 
criteria were applied to patients (no provider link, wrong age, death within the time
frame, etc.) and providers (no prescriptions in that time period, not hired in the right time
frame), the only remaining unknowns had basic demographic data (gender, specialty, and 
type), and thus were included in the analysis, though their birthdates, hiring dates, and 
fulltime status were not available. These “unknown” providers were all physicians and 
more likely to be specialists (58% versus 42%). They also had many fewer patients in the
study (mean of 3 patients each versus 153 for the rest of the providers). As a result, their 
drug prescribing frequency was lower and the number of medications they prescribed was
smaller.
v. Drug-Test Pair Characteristics
Because we know that physician clinical practice behavior is affected by level of
evidence and guidelines to various extents,50, 88 we included measures of whether the
study drug-test pairs were included in BBWs or in clinical guidelines. For the analysis of
factors associated with ordering (this study) and completion (Chapter V), each drug-test 
pair was additionally categorized based on the evidence basis for the test. In general, the
level of evidence for medical guidelines widely varies, with as many as half of guideline
recommendations based on low-quality evidence.89 It is outside the scope of the parent
project or of this dissertation to exhaustively review the literature to summarize the levels
of evidence for each and every drug-test pair. Instead, we have started with the premise
  
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
  
 
71
that drug manufacturers’ recommendations for monitoring represent knowledge of and 
evidence of harm. Ample recent evidence demonstrates that drug manufacturers are well
aware of the potential of harm from their products and actively work to suppress the
public release of this knowledge.90 Therefore, there is a publication bias that hampers any 
systematic effort to document levels of harm. Furthermore, this absence of information 
and recent history with documented harm in post-marketing surveillance studies (e.g., the
case of rosiglitazone/Avandia91-93) demonstrates a lag in the knowledge of drug harm
relative to FDA approval. 
Therefore, we used the following approach to classify the monitoring guidelines. 
•	 At the highest level, we identified whether there were BBWs on specific medications
recommending certain tests. These warnings, which can be required by the FDA, are
the most serious warnings in prescription drug labeling. Therefore, the presence of
such a warning suggests strong evidence of risks associated with the medication as
well as serious quality of care implications for not heeding the warnings. Even these
are inconsistently reported,94 and adherence is poor even to these warnings,95, 96 but
they are validated, well-disseminated, and the strongest form of guideline available to 
a practitioner, thus most likely to drive ordering behavior. These drugs are commonly 
prescribed.95 
•	 We next identified guidelines by physician practice groups or quality of care
organizations with recommendations for monitoring.
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•	 At the next level, we classified drugs for which there were no clear guidelines, but for 
which testing was recommended in standard references, specifically UpToDate, 
Micromedex, Pharmacist’s Letter, and the Physician’s Desk Reference.
•	 Separately, laboratory testing occurs to monitor clinical efficacy or toxicity in drugs
with narrow therapeutic windows. We created a separate category to classify these
monitoring guidelines.
vi. Conceptual Framework for Analytic Strategy
Variables included in this analysis were selected based on Anderson’s model of
health services use which can be used to guide analyses of the association between 
patient factors, physician factors, and health service utilization (i.e., laboratory 
monitoring of prescription medications). This model generally looks at the behavior of
patients and families, and it classifies predictors of behavior into three categories:
predisposing factors refer to demographic factors like age and gender as well as family 
structure and health beliefs that affect service use; enabling factors, resources that
promote or inhibit use like income and health insurance; and needs factors, the illness
and circumstances that necessitate use.30, 31 
Outcome variable:
Ordered status for a monitoring test, dichotomous for each patient-drug-test 
combination (1=ordered, 0=not ordered), based on the electronic record, was the outcome
variable.
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Key predictor variables:
Provider characteristics, including gender, age (continuous and by decade), type
(physician, nurse practitioner, physician assistant, or other), primary care provider versus
specialist, full-time working status, years of experience (continuous), frequency of
prescribing a given drug (continuous and quartiles), and number of patients to whom drug 
was prescribed (continuous and quartiles) were included. Provider variables that were not
in or calculable from the EMR (such as full-time status and year of hire and graduation) 
were captured deidentified from the practice’s employment database.
Other variables
Patient characteristics, including age (continuous and by decade), gender, number 
of study prescriptions (categorized into two and three groups), and visit frequency 
(continuous and quartiles), as well as specific diagnoses including dementia and heart
disease (categorical), and number of other study medications were included. Comorbidity 
was measured using the Charlson score using ICD-9 codes from encounter data in the
EMR via a tool in STATA using ICD9 codes.97 The Charlson score is correlated with 1-
year mortality98 and is the most widely used comorbidity index.99 We examined both the
weighted index (0-16) and a categorical three-point index (0-2) defined as a weighted 
Charlson of 0, 1, or !2. The Romano adaptation of the Charlson score was also calculated 
in STATA from the disease-specific scores and also categorized into a dichotomous
variable (Romano "2 vs. Romano ! 3).100 
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Prescription characteristics, including drug, evidence for testing category (BBWs, 
other type of guideline, and testing for narrow therapeutic window category), whether the
drug had single or multiple recommended tests, and testing frequency were included. The
BBW category was identified by individually checking whether a given test addresses a
warning via online databases (labeling only relevant drug-test combinations as BBW, not
by drug) with the caveat that even BBW status is reported differently in different
locations.94 
For analysis, we categorized many continuous variables into quartiles to account
for possible non-linearity. For example, we calculated quartiles for visit number per 
patient, drug prescribing frequency for providers, prescription number per provider, and 
number of patients per provider. We categorized age by decade, starting with patients and 
providers below 40 and ending with providers >60 and patients >80, due to frequencies. 
We also categorized the number of drugs per patient (which ranged from 1 to 9) to a
dichotomous variable (one or more than one), and to three categories, 1, 2-4, and 5-9, to 
enable comparison to similar studies.96 
vii. Data Analysis
Using the integrated EMR, prescriptions and laboratory orders were extracted for 
the study time period. Each prescription, linked to scrambled IDs for both prescriber and 
patient, were then linked to laboratory orders for the patient in question during the
relevant time period, as well as to demographic and medical information for provider and 
patient.
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Our analytic modeling strategy accounted for multiple prescriptions nested within 
a patient and multiple patients nested within a provider. The unit of analysis was a
prescription-test pair. The outcome was whether an indicated test was ordered (yes/no). 
For each prescription, the recommended test was either ordered or not, resulting in a
“yes”/”no” for “test ordered.”
Because some patients have multiple providers who prescribed them study 
medications as well, we initially developed a series of unadjusted and adjusted models
that accounted for crossed effects in our analysis. In this approach, we used a multilevel
mixed-effects logistic regression specifying both patients and providers as random
effects. Initial models examined predictor variables individually, and subsequent
multivariable models further adjusted for potential confounders. However, most
multivariable models did not converge because of the high prevalence of patients with 
single tests as well as perhaps because some providers had single patients.
We therefore developed logistic regression models with a robust covariance
estimator (sandwich estimator) to adjust standard errors for clustering. This approach 
provides conservative nonparametric estimates101-104 We first calculated robust standard 
errors based on clustering of medications within patient and separately performed 
calculations based on clustering within providers. The models with patient and provider 
clustering both produced similar parameter estimates to each other, as well as to the
cross-effect models when they did converge, but when we clustered by provider the
models yielded more conservative estimates of the standard errors and therefore is what
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we present here. Parameter estimates are reported as odds ratios (ORs) of factors
associated with test ordering.
Our modeling approach aimed to develop an explanatory model to identify factors
that could be changed through intervention, rather than simply to obtain a best predictive
model.105 Therefore, initial models included all factors hypothesized to be associated with 
test ordering a priori. Unadjusted models examined relationships between each predictor 
and confounding variable with the outcome of test ordering. We also tested for 
correlation between patient visits, Charlson comorbidity score, and Romano comorbidity 
score, and found correlation among these variables at the #>0.40 level given that they all
reflected patient health status. Therefore, we only included the number of patient visits as
the single health status proxy indicator in each model. We developed separate models for 
Charlson scores and Romano scores in sensitivity analyses. Similarly, prescribing 
frequency and patient panel size were correlated, leaving us to include only one volume
measure in each adjusted model. We also examined for interactions of BBW (yes/no) 
status with provider status and number of drugs per patient. Because we found a
significant interaction of BBW in adjusted analysis, we developed models stratified by 
BBW. Final multivariable models included factors hypothesized to be associated with test
ordering a priori and factors associated with test ordering at the p<0.20 level in 
unadjusted analysis. Goodness of fit for the models were examined using the c statistic
and receiver operating characteristic (ROC) curve.
Analyses were conducted in SAS 9.2 (SAS Institute, Cary, NC) and StataSE 
(Stata Statistical Software: Release 11.1, Stata Corporation, College Station, TX, USA).
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D. Results
i. Patient Population and Use of Medications Requiring Laboratory Monitoring
After excluding ineligible patients, providers, and prescriptions and after linking 
all prescriptions to patients and prescribing providers, the study data included 31,417 
unique patients and 278 providers for a total of 65,135 drug-test pairs. This included 
prescriptions for 34 high-risk medications or medication classes, some of which had 
multiple recommended tests, for a total of 60 drug-test combinations (Table 4.1).
ii. Provider Characteristics
Primary care caregivers accounted for about 56% of the prescribers, including 
primary care nurse practitioners, and physician assistants. The most frequent specialty 
was Internal Medicine followed by Family Practice and Pediatrics (who often see patients
well beyond age 18). The mean number of prescriptions per provider was 215, with 50 
percent of providers having between 3 and 247 prescriptions. Providers had as few as 1 
patient or as many as 784 to whom they prescribed a medication in the study, with 50% 
having 2 to 179 patients. The mean number of times a given drug was prescribed by a
provider was 43, though that ranged from once to 420 prescriptions of the same
medication in the study period. 47% of patients had a single prescription in the study, 
with 98% having 4 or fewer but some having as many as nine prescriptions of study 
medications. BBW drug/test combinations made up 16% of all prescriptions. Baseline
characteristics of patients and providers are described in Table 4.2 (not all information 
was available for all providers).
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Table 4.2: Summary of Provider and Patient Characteristics 
Providers  N, of 278 providers 
Mean age (years) 48.1 235 
Female 42.6% 275 
Physician vs. other kind of prescriber 86.0% 278 
Primary care physician (PCP) vs. specialist 56.3% 247 
Fulltime 74.4% 195 
Years of experience (years since graduation) 20.3 235 
Mean number of prescriptions in study 215 278 
   
Patients  31,417 
Mean age (years) 66.1  
Female 56.8%  
Study medications per patient 1.9  
   
Drug-test pairs  65,135 
New vs. chronic use 38.6% new  
Black box warning 15.6%  
iii. Unadjusted Analysis 
 Many variables were significantly associated with rates of test ordering (Table 
4.3). Of particular interest was the BBW status of the drug-test pair, which was 
associated with higher rates of ordering (OR 1.18 compared to all other prescriptions, 
p<0.001); having multiple providers, which increased ordering (OR 1.34, p<0.001); 
primary care status of provider, which increased ordering (OR 1.67, p<0.001); age of the 
patient, which was associated with increased ordering (OR by year 1.03, p<0.001; OR 
4.48 for >70 years old compared to <40, p<0.001); and user status, in which new user 
status decreased ordering (OR of 0.45, p<0.001). Provider characteristics like fulltime 
status and years of experience were not significantly associated with ordering, though the 
number of drugs per patient (OR 1.33, p<0.001 for each additional study drug a patient 
was prescribed) and the number of prescriptions by provider (OR 6.6 for top quartile 
compared to the bottom, p<0.001) were both associated with increased test ordering. 
Frequency of prescribing a drug was also correlated with ordering, with the highest 
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frequency quartile prescribed associated with test ordering more than twice as often as 
those prescribing least often (OR 2.41, p<0.001). Drugs-test pairs with multiple tests or 
with tests to be ordered more frequently were less likely to have tests ordered (OR 0.49 
and 0.34 p<0.001 for both). Sicker patients were more likely to have a test ordered, 
whether measured by Charlson score (OR 1.3 and 1.8, p<0.001, for Charlson Index = 1 or 
2, respectively), by Charlson summary score (OR 1.14 per unit of score, p<0.001), 
Romano high status (OR 1.7, p<0.001), and quartile of visit number (1.9, 2.5, and 3.2, 
p<0.001 for all).  
Table 4.3: Unadjusted Characteristics Associated with Ordering Rate 
Patient characteristics Unadjusted Odds 
Ratio (OR) [95% 
Confidence Interval 
(CI)] 
Patient gender   
Male 1 [Reference] 
Female 0.93 [0.84 – 1.03] 
Patient age   
<40 years old 1 [Reference] 
40-50 1.75 [1.56 – 1.97] 
50-60 2.42 [2.14 – 2.74] 
60-70 3.72 [3.20 – 4.31] 
70-80 4.47 [3.88 – 5.15] 
≥80 4.49 [3.91 – 5.15] 
Number of patient visits (quartiles)  
0-5 visits 1 [Reference] 
6-10 visits 1.91 [1.75 – 2.09] 
11-18 visits 2.46 [2.20 – 2.76] 
≥19 visits 3.16 [2.82 – 3.53] 
Charlson score   
Charlson score = 0 1 [Reference] 
Charlson score = 1 1.27 [1.17 – 1.38] 
Charlson score ≥ 2 1.80 [1.67 – 1.95] 
Romano index  
Romano index < 3 1 [Reference] 
Romano index ≥ 3 1.67 [1.53 – 1.81] 
Specific diseases, compared to not present   
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Heart disease 1.77 [1.59 – 1.96]
Dementia 0.73 [0.60 – 0.90]
Number of providers per patient
One 1 [Reference]
More than 1 1.34 [1.21 – 1.49]
Number of study drugs patient is taking
Single drug 1 [Reference]
Multiple drugs 2.13 [1.98 – 2.28]
Provider characteristics
Provider gender
Male 1 [Reference]
Female 0.92 [0.73 – 1.16]
Provider age
<40 years old 1 [Reference]
40-50 years old 0.89 [0.67 – 1.18]
50-60 years old 0.82 [0.63 – 1.07]
>60 years old 0.40 [0.31 – 0.51]
Provider specialty
Specialist 1 [Reference]
PCP 1.67 [1.23 – 2.26]
Provider type
MD 1 [Reference]
NP 0.92 [0.59 – 1.44]
PA 0.76 [0.57 – 1.00]
Provider years at this health care system 0.99 [0.98 – 1.01]
Provider years since graduation 0.98 [0.97 – 1.00]
Working status
Part-time 1 [Reference]
Fulltime 1.25 [0.95 – 1.63]
Prescriptions per provider
First quartile (<3 prescriptions) 1 [Reference]
Second quartile (3-12) 2.24 [1.38 – 3.66]
Third quartile (13-247) 4.59 [2.91 – 7.25]
Fourth quartile (!216) 6.55 [4.28 – 10.04]
Patients per provider
First quartile (1 patient) 1 [Reference]
Second quartile (2-11) 1.58 [0.84 – 3.00]
Third quartile (12-179) 3.68 [1.96 – 6.88]
Fourth quartile (!190) 4.97 [2.71 – 9.10]
Prescription characteristics
Evidence for test
Recommended test 1 [Reference]
BBW 1.29 [1.11 – 1.51]
Guidelines 1.49 [1.28 – 1.75]
Evidence base
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Other 1 [Reference]
Narrow therapeutic window 0.45 [0.37 – 0.54]
Test frequency
Yearly 1 [Reference]
More frequent 0.34 [0.25 – 0.46]
Prescription type
Chronic use 1 [Reference]
New use 0.45 [0.42 – 0.49]
Multiple vs. single test for this drug
Single test 1 [Reference]
Mutliple tests 0.49 [0.42 – 0.58]
Abbreviations: BBW, black box warning; MD, medical doctor; NP, nurse practitioner; PA, physician
assistant; PCP, primary care provider.
iv. Multivariable analysis
In multivariable analyses, the final models included the following variables:
primary care status or patient volume, BBW or other evidence level, patient health status, 
and sex, age, and gender covariates for prescribers. We included patient age, gender, 
BBW status, and provider specialty a priori, and because of significance kept in the
model the following additional covariates: number of drugs per patient, number of
providers per patient, patient comorbidities, test frequency, new or chronic use, number 
of tests per drug, number of patients per provider, provider experience, and provider type
(Table 4.4).
Prescriptions without BBWs, those for patients who were healthier, and those
written by providers who were older were again associated with lower ordering. Tests
that were to be ordered more frequently were also less likely to be ordered, and patients
on only one medication were less likely to have a test ordered, as were female patients. 
Older patients were more likely to have tests ordered, as were patients with more visits in 
the study year. There was also a significant interaction between the BBW status and the
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number of drugs a patient was taking, with BBW status having a larger effect among 
those on more medications. 
 Sicker patients were more likely to have a test ordered in the multivariable model. 
We included a model using number of visits as a proxy for health status in Table 4.4 (OR 
of 2.6 for top quartile compared to bottom quartile, p<0.001); models using Romano 
comorbidity (OR 1.3, p<0.001) and Charlson Score (OR 1.1 and 1.4 for Index = 1 and 2, 
respectively, both p<0.05) yielded similar results. The model with visit number has a c 
statistic of 0.72, while the model using the Romano variable had a c statistic of 0.70. 
Similar models using the Charlson score, whether categorized or not, also had c statistics 
of 0.70. 
 Certain variables were closely related. For example, primary care providers had 
much larger patient panels (number of patients) than their specialist colleagues, resulting 
in an association between patient number or prescription number and specialty status. In 
the unadjusted model, both primary care status and provider volume, however measured, 
were associated with higher ordering rates, and these two categories were associated with 
each other. 
Table 4.4: Adjusted Model: Factors Associated with Ordering, Including 
Stratification by BBW 
Stratified Models Variable Unstratified Fully 
Adjusted Model 
N=60347 
OR [95% CI] 
Non-BBW pairs 
N=51132 
OR [95% CI] 
BBW pairs 
N=9215 
OR [95% CI] 
Patient gender       
Male 1 [Reference] 1 [Reference] 1 [Reference] 
Female 0.83 [0.75 – 0.92] 0.85 [0.76 – 0.94] 0.79 [0.64 – 0.98] 
Patient age       
<40 years old 1 [Reference] 1 [Reference] 1 [Reference] 
40-50 1.38 [1.21 – 1.57] 1.14 [0.98 – 1.33] 1.45 [1.12 – 1.88] 
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50-60 1.74 [1.56 – 1.95] 1.38 [1.21 – 1.57] 1.96 [1.51 – 2.56] 
60-70 2.25 [1.95 – 2.58] 1.73 [1.48 – 2.01] 3.06 [2.28 – 4.12] 
70-80 2.19 [1.89 – 2.54] 1.68 [1.41 – 2.00] 3.36 [2.57 – 4.39] 
≥80 2.04 [1.73 – 2.41] 1.59 [1.30 – 1.93] 3.06 [2.29 – 4.08] 
Number of patient visits, by quartile       
0-5 visits 1 [Reference] 1 [Reference] 1 [Reference] 
6-10 visits 1.65 [1.50 – 1.82] 1.64 [1.48 – 1.81] 2.00 [1.58 – 2.53] 
11-18 visits 2.02 [1.78 – 2.30] 2.04 [1.78 – 2.34] 2.38 [1.91 – 2.97] 
≥19 visits 2.63 [2.26 – 3.06] 2.56 [2.19 – 3.00] 4.54 [3.55 – 5.80] 
Number of study drugs patient is taking       
Single drug 1 [Reference] 1 [Reference] 1 [Reference] 
Multiple drugs 1.55 [1.43 – 1.68] 1.55 [1.44 – 1.68] 1.77 [1.46 – 2.14] 
Number of providers per patient       
One 1 [Reference] 1 [Reference] 1 [Reference] 
More than one 0.98 [0.88 – 1.10] 0.97 [0.87 – 1.09] 1.00 [0.78 – 1.27] 
Provider gender       
Male 1 [Reference] 1 [Reference] 1 [Reference] 
Female 0.81 [0.58 – 1.13] 0.82 [0.58 – 1.15] 0.82 [0.54 – 1.23] 
Provider age       
<40 years old 1 [Reference] 1 [Reference] 1 [Reference] 
40-50 years old 0.80 [0.52 – 1.23] 0.81 [0.51 – 1.27] 0.60 [0.34 – 1.06] 
50-60 years old 0.71 [0.40 – 1.28] 0.67 [0.37 – 1.20] 0.86 [0.35 – 2.10] 
>60 years old 0.30 [0.13 – 0.70] 0.30 [0.12 – 0.72] 0.48 [0.14 – 1.64] 
Provider specialty       
Specialist 1 [Reference] 1 [Reference] 1 [Reference] 
PCP 0.71 [0.45 – 1.10] 1.01 [0.68 – 1.52] 0.30 [0.15 – 0.62] 
Patients per provider       
First quartile (1 patient) 1 [Reference] 1 [Reference] 1 [Reference] 
Second quartile (2-11) 2.16 [0.93 – 5.02] 2.19 [0.69 – 6.92] 2.33 [0.86 – 6.31] 
Third quartile (12-179) 2.77 [1.22 – 6.30] 2.16 [0.72 – 6.51] 4.65 [1.85 – 11.70] 
Fourth quartile (≥190) 3.38 [1.49 – 7.64] 2.65 [0.87 – 8.02] 5.15 [2.12 – 12.55] 
Working status       
Part-time 1 [Reference] 1 [Reference] 1 [Reference] 
Fulltime 1.05 [0.75 – 1.48] 1.13 [0.81 – 1.59] 0.86 [0.53 – 1.39] 
Years of experience, per year 1.00 [0.97 – 1.03] 1.00 [0.97 – 1.03] 1.00 [0.96 – 1.04] 
Prescription type       
Chronic use 1 [Reference] 1 [Reference] 1 [Reference] 
New use 0.52 [0.48 – 0.56] 0.57 [0.52 – 0.62] 0.39 [0.31 – 0.49] 
Evidence for test       
Recommended test 1 [Reference] 1 [Reference] 1 [Reference] 
BBW 1.78 [1.49 – 2.13]     
Guidelines 1.31 [1.10 – 1.56]     
Test frequency       
Yearly 1 [Reference] 1 [Reference] 1 [Reference] 
More frequent 0.38 [0.29 – 0.49] 0.51 [0.39 – 0.65] 0.18 [0.13 – 0.24] 
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Number of tests recommended for this 
medication       
Single 1 [Reference] 1 [Reference] 1 [Reference] 
Multiple 0.48 [0.40 – 0.57] 0.43 [0.37 – 0.51] 0.62 [0.38 – 0.99] 
Abbreviations: BBW, black box warning; CI, confidence interval; OR, odds ratio; PCP, primary care 
provider. 
Subanalysis – stratification 
 We ran the same model stratifying by BBW status of the drug-test pair. The BBW 
subgroup model had a c statistic of 0.83, while the non-BBW model had a c statistic of 
0.70. The relationships of the covariates were the same when stratified, except for 
provider type: PCPs were more likely to order a test in the lower-risk pairs, though not 
significantly (OR 1.01, p=0.943), while in the drug-test pairs with warnings, PCPs were 
much less likely, compared to specialists (OR 0.30, p=0.001). This interesting difference 
may be related to the panel size of PCPs (25 mean number of patients for specialists 
versus 227 for PCPs) and the number of different drugs prescribed by each (4.6 for 
specialists versus 12.7 for PCPs). Specialists are more likely to be prescribing the drugs 
in the BBW pairs, meaning that even if the two types of providers are ordering tests at 
similar rates (unadjusted and not clustered, PCPs ordered for 75% of indicated tests, 
while specialists did 67% of the time), specialists would have more opportunities with the 
BBW drug-test pairs. 
E. Discussion 
 Our results suggest an association between many factors and test ordering rate of 
high-risk medications in the ambulatory setting, most notably the provider specialty 
status (specialists ordering less often), the medical status of the patient (healthier patients 
having lower rates of test ordering), provider volume (number of patients and frequency 
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of prescribing) and both provider and patient age (more test ordering was associated with 
older patients and younger providers). Provider full-time working status and years of
experience were not related to ordering rates given provider age.
Little is known about physician factors associated with medication test
monitoring. Prior studies have shown that barriers to monitoring identified by physicians
include lack of clarity regarding which physician was responsible, uncertainty about the
necessity of monitoring in the first place, a lack of automated reminders, and physician 
specialty, as well as patient non-adherence with their recommendations.26 However, 
physician characteristics such as experience and prescribing volume have not been 
examined, and physician demographics associated with monitoring are relatively 
understudied. One study found that younger physicians and female physicians were more
likely to order potassium tests for patients on diuretics,10 and another study focused on 
prescribing showed that patient factors like sex and worsening renal function might drive
provider compliance with alerts for medication dosing.106 More is known about physician 
factors associated with patient attendance at appointments, but studies focused on health 
system factors such as waiting time107 and scheduling errors.108 Patient factors such as
sex and age may also contribute to monitoring,109 though whether those effects are due to 
changes in ordering rates or in completion rates has not previously been examined.
i. Physician Adherence to Guidelines
One major factor in adherence to monitoring is adherence to clinical guidelines, 
which is known to be low.16, 110, 111 Overall, in one study, general guidelines were
followed one 67% of the time, with large variations between physicians and between 
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guidelines88 We expected poorer adherence when providers believed guidelines less
strongly, though outcomes research suggests few incidents have resulted from non-
adherence to even the strongest guidelines,95, 112 and when specific interventions are
introduced to target adherence to BBWs, improvement is limited, if there is any.96 BBWs
as a class include varying levels of alerts,96 perhaps accounting for the low overall
adherence rate to monitoring recommendations even in this class, below 50% in one
recent study.66 
The reasons for physician non-adherence are complex. In addition to lack of
familiarity with guidelines, research suggests other barriers to guideline adherence
include lack of awareness, lack of agreement/expectation of outcomes, lack of self-
efficacy, inertia, and other external barriers.113 A recent focus group series with 
physicians on adherence to guidelines suggests a taxonomy including concerns about
patient adherence and patient preferences as well as provider-centered concerns such as
limited benefits and causing adverse events.114 Even when providers are aware of
guidelines and want to follow them, they are often difficult to interpret: more than half of
the BBWs in one study required clarification from a specialist.95 Doctors addressing 
multiple issues may also have their attention divided, as suggested by the theory of
competing demands, making more complicated patients less likely to get certain 
treatments.115, 116 Individual patient circumstances may also influence decision-making95 
and receptiveness to certain interventions,117 which is why this study analyzes patient
factors as well as provider factors. In some cases, providers may doubt the credibility or 
applicability of guidelines, particularly with proscriptive guidelines,118 and perhaps with 
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good reason, as many guidelines have little evidence for an effect on patient outcomes.112 
However, even good evidence and good source credibility do not ensure adherence.27 
To maximize adherence to guidelines, a few recommendations have been made. 
As advised for effective clinical support,38 and in general for all behavioral change,119 
having guidelines customized to the situation and available at the time of ordering could 
increase adherence; for example, when antibiotic guidelines were made available
electronically at the time of computerized ordering, but no requirement to follow them
was made, non-conformity with guidelines decreased.120 Tiering electronic alerts, with 
more severe interruptions for more dangerous actions, also increases physician adherence
to alerts,121 suggesting that perhaps stronger evidence could affect behavior, though 
again, this has not always been the case in the past.
Other factors contributing to adherence are addressed below, including the level
of available evidence and provider specialty.
ii. Levels of Evidence
Past research has rarely addressed the question of provider factors associated with 
ordering of monitoring tests. However, physician adherence to guidelines overall and to 
black box warnings in particular has been examined. Another study on black box 
warnings concluded in multivariate analysis that older patients, healthier patients, and 
patients at a hospital-based clinic were prescribed medications in violation of BBW at a
higher rate than others.96 Our results somewhat differed. We did not find a strong 
association between the number of prescriptions and number of BBW prescriptions. 
However, we found the odds ratios for ordering to be significantly higher for BBW in 
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both older patients and sicker patients, often across groups, and in those patients on more
medications. Thus while ordering rates for BBW drug-test combinations are certainly not
high enough, we also need to consider the recommendations with less evidence and 
determine whether those testing need to be targeted for increase or whether better 
evidence needs to be gathered to support the guidelines.
As in previous studies,88 we found a large amount of variation for adherence
between guidelines and a large portion of the variation could be attributed to variation 
among physicians, greater than that attributable to the variation among patients.
iii. Volume
Surgical literature has long shown an association between procedure volume and 
outcomes. Recent work on quality indicators also suggests an association between 
frequency of prescribing or treating and associated quality indicators.122 Generally, 
volume is associated with better adherence,123 though in some studies, increased provider 
volume has shown decreased adherence to surveillance guidelines.124 Our results show a
relationship between number of patients and frequency of prescribing and ordering rates, 
suggesting familiarity with a medication increases adherence to testing guidelines, with 
providers with the top quartile of patients 3.4 times as likely to order a test as those in the
bottom quartile (p=.003). Whether measured by patient panel size, prescription number, 
or frequency of prescribing a specific drug, those providers in the top quartile were 2.4-7 
times as likely to order a test in the unadjusted models (p<.001 for each of these
variables) and as high as 5 times as likely (p<.001) in the adjusted models. Thus volume
plays a major role in test ordering.
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iv. Specialists versus Generalists
Past research has found that specialists showed greater adherence to expert
guidelines87 and has suggested better care among specialists as compared to generalists, 
though the effects on outcomes were stronger in the hospital setting as compared to the
ambulatory setting.85, 86, 125 We found a relationship between frequency of prescribing a
medication and ordering rate.
However, our findings also show that when primary care providers prescribed 
medications, they were actually more likely to have tests ordered, and when factors such 
as volume were included in the model, this difference disappeared, suggesting familiarity 
with the medication because of frequency of prescribing was a main factor affecting this
result. However, when stratified by evidence level, specialists were more likely to order 
tests in those drug-test pairs with stronger warnings (BBW), suggesting that for those
drug-test pairs, which are prescribed more often by specialists, those providers are more
likely to follow the guidelines. This may be related to prescribing frequency as well.
v. Strengths
A major strength of this study is its data source: the electronic nature of the
records allowed us to track a medication from prescription through test ordering (and in a
another paper, we will also examine test completion). As noted in the literature, 
combining laboratory and medication data allows for evaluating the quality of treatment, 
studying adverse events, and investigating drug-test interference.18, 19 Furthermore, 
because we have information about both providers and patients in an electronic system, 
we have been able to study associations with test ordering that have not been previously 
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reported, such as provider specialty, provider volume, and years of practice. As we noted 
earlier, even in places with electronic ordering of tests, it is often difficult to track which 
tests are completed.33 We were able to directly link providers with their prescriptions and 
their patients along with orders and their completion through a single electronic system.
vi. Limitations
As previously noted, the patients receiving care from Fallon Clinic are
representative of the population of central Massachusetts. However, although Fallon 
Clinic is similar to many similar healthcare provider groups across the US and its patient
population is broadly representative, it is different in that it is an integrated health care
system and it is one of the early providers to have full implementation of electronic
medical records and computerized physician order entry. Similarly, Fallon Clinic
providers represent a range of experience and specialties, but employees of a
multispecialty group practice may differ from private practitioners and hospital-based 
providers. Furthermore, we had detailed information about specialty and years of
experience for Fallon Clinic providers, but for providers who have submitted orders
through the Fallon EMR but are not Fallon Clinic providers, we did not have the same
extensive data. For our analysis, we included as much information as we had. Providers
from outside Fallon Clinic may differ in some ways from Fallon clinic providers.
As in Chapter III, we may have missed monitoring that was done at a hospital, 
and we were unable to confirm patient adherence to drugs or patients who did not
complete tests because they were no longer using the medication for whatever reason.
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Also, we chose to use claims data because of the potential bias of including 
prescriptions from the electronic record that patients were not taking or had not even 
filled. Many prescriptions are not “discontinued” when patients cease to take them, even 
when the provider is informed, making the EMR somewhat unreliable for current
medications. Claims data, in contrast, only reflect prescriptions that have been filled. 
However, claims data also have their shortcomings, as they do not include the increasing 
number of medications for which patients are paying in cash through special discount
programs at large pharmacy chains. However, we would rather underestimate medication 
use than overestimate medication use.
vii. Implications for Practice
While electronic interventions have not been consistently successful in improving 
monitoring rates thus far,23 the potential for such tools to be effective at increasing 
safety21 and improving patient outcomes126 remains. Much depends on how these
interventions are designed126 and analyzed,23 however, and many reminders have had less
of effect on provider behavior than expected or hoped.127 
Variation in adherence even to BBW shown in our results and elsewhere
emphasize the importance of having guidelines based on strong evidence, easily 
accessible, and, ideally, in a computerized format to maximize adherence.120 At the same
time, we should be less concerned about providers following guidelines that don’t have
good evidence. Therefore, while providers should continue to be encouraged to follow
evidence-based guidelines, researchers, professional societies, and other leaders in 
  
 
 
 
   
 
 
 
 
 
 
 
92
medication guidance and safety should continue to pursue strong evidence for those
guidelines as well as making them clear enough to not require interpretation.
Also, as recommended elsewhere,27, 95 guidelines and warnings should be more
specific and frequently updated so providers will be able to follow them and to rely on 
them.
Interviews with providers suggest they are open to computerized reminders26 and 
to clinical decision support in general if it is designed well, not too sensitive, and 
minimally interruptive.128-130 Primary care providers said that they can comply better with 
guidelines given electronic clinical reminders (79% in one survey131) although they may 
be less likely to do so when behind or when managing complicated patients.132 Another 
study, however, showed physicians were more inclined to use an electronic prescribing 
system for patients who used more medication, made more emergency department visits, 
had more prescribing physicians, and had lower continuity of care.117 Our study had 
similar findings as this study on prescribing, with sicker patients receiving more
appropriate test orders.
Thus we see: 1) the importance of having data electronically so as to be able to 
separate ordering and completion and actually report ordering accurately; 2) the
importance of having evidence-based recommendations for quality of care as well as for 
adherence; and 3) the power of technology to facilitate guideline delivery to the right
person at the right place and time. While providers are open to these interventions, other 
systems factors may impact laboratory monitoring, such as accuracy of medication lists, 
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ease of ordering, communication among providers, and of course, patient completion, 
which we address in the next chapter.
viii. Future Research
Because patients with fewer interactions with the health care system have fewer 
tests ordered, research involving contacting patients directly about unordered tests could 
be a path to increased testing ordering.
It must also be noted that ordering differences between provider types may have
to do with the quality of communication between specialists and generalists, with 
specialists expecting generalists to order monitoring for medications the specialists
prescribed: a secondary analysis, to be pursued in more depth in the future, will look at
the cases where the provider who ordered the test is not the same provider as the one who 
prescribed the medication. 
Similarly, in some cases, a test was ordered appropriately for a patient by 
someone other than the prescribing provider. Patients often have more than one provider 
(15% of our population had prescriptions for study drugs from at least two providers) and 
of course providers generally had more than one patient, even in this limited dataset
(mean of 132 patients for whom each provider in the study wrote a study prescription), so 
our data contained multiple patient-provider relationships. This slightly complicated the
question of giving a provider credit when a test was ordered. Future research will
examine the role of the prescriber separately from that of the orderer. However, past
research suggests that it is reasonable to hold a provider accountable for a quality event if
the patient had a visit with this physician during a time frame during which the provider 
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could have fulfilled this requirement,122 which is the case for our prescribers. This applies
to laboratory monitoring as well as to other quality indicators.
ix. Conclusion
This study had novel findings in factors associated with test ordering for 
ambulatory patients taking high-risk medications. Older and sicker patients and those
with more interactions with the health care system were more likely to have testing 
ordered, as were tests for drug-test combinations with black box warnings. This higher 
rate for BBW combinations indicates that these warnings have permeated provider 
consciousness and suggests a role for provider education and reminders in improving test
ordering.
Further research should use electronic data and should focus on interventions on targets
with the greatest potential for improvement, like younger and healthier patients, on 
medications with evidence of harm, even when not as well established, and for providers
who have less familiarity prescribing a given medication. Patients with less interaction 
with the health care system are also at risk of not having tests ordered and perhaps should 
be reminded and scheduled for laboratory testing to ensure completion. Lastly, guidelines
should be clarified, consistent, and frequently updated so that providers can follow the
best evidence in treating their patients. 
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CHAPTER V
 
FACTORS ASSOCIATED WITH COMPLETION OF
 
MONITORING FOR HIGH-RISK MEDICATIONS
 
A. Abstract
Purpose
To determine patient factors that contribute to completion of ordered monitoring tests for 
high-risk medications. We hypothesized that sicker patients, patients with psychiatric
illnesses, younger patients, and patients with tests ordered for a date in the future rather 
than the same day would be less likely to complete an ordered test after adjusted for 
provider characteristics such as specialty.
Design, Participants, Measures, and Data Analysis
As in Chapter IV, we performed a cross-sectional analysis of the administrative claims
and electronic medical records of patients prescribed a high-risk medication requiring 
laboratory monitoring in a large multispecialty group practice between January 1, 2008 
and December 31, 2008. For this analysis, we only included patients for whom a
monitoring test for one of these medications was ordered. The outcome was patient
completion of the ordered monitoring test. Key predictor variables were patient
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characteristics such as age, gender, and comorbidities. Potential confounders include
provider characteristics such as specialty and drug-test characteristics. We used 
multivariable logistic regression to identify the independent association of patient
characteristics with completion of laboratory tests, after controlling for potential
confounders. We used robust standard errors to account for clustering of patients within 
providers.
Results
Patient completion of ordered laboratory tests varied across drug-test pairs and ranged 
from 71% (Terbinafine–AST) to 100% (Cyclosporine–Cyclosporine level, all Quinidine
tests, and a few other infrequent drug-test pairs). Completion rates were associated with 
patient age, number of drugs per patient, and visit frequency, though not with other 
comorbidity measures. Provider factors such as specialty did not affect completion. 
Highest risk drug-test pairs, measured by black box warning status, were associated with 
decreased odds of test completion.
Conclusions
Patients with more physician visits and higher medication burden were more likely to 
complete ordered laboratory monitoring for high-risk medications. Interventions targeting 
patients should be addressed to those subgroups with the greatest potential for
improvement.
  
 
  
    
 
 
 
 
  
 
 
  
 
 
 
 
 
  
 
 
97
B. Background
It is established that prescription medications often cause injury,3, 57 and that
failure to monitor high-risk medications is one of the leading factors contributing to 
adverse drug events (ADEs).3 While improvements in ordering rates by physicians could 
contribute to better monitoring, another major factor in low monitoring rates is patient
non-completion of ordered tests.
However, as we demonstrated earlier, studies looking at laboratory monitoring 
generally do not measure both rates of ordering and rates of completion.23 Most studies
report only test completion rates,10-12, 24, 58 but without noting whether tests were ordered, 
it is difficult to attribute the non-testing to patient behavior. Furthermore, little research 
has been done on the patient factors that contribute to adherence to ordered laboratory 
monitoring.
Patient non-adherence to medications has been shown to contribute to preventable
adverse drug events,3 and has been shown to be low in general, depending upon various
factors including type of medication.28 Visit frequency has been shown to be associated 
with medication adherence,133 whether on its own or as a proxy for severity of illness; it
is likely that it is also a factor in completion of ordered monitoring.
The actual reason for missing appointments has not been studied closely,29 with 
only a few factors leading to non-attendance identified by patients, such as waiting time
and the respect patients felt the health care system afforded them.67, 73 Some factors have
been shown to correlate with appointment non-attendance: associated patient
characteristics include being a young adult, having small children, lower socioeconomic
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status, and longer time to appointment;68 male sex, younger age, summer vacation, and a
first time visit;69 feeling better, transport problems, and, in contrast, short notice;62 male
sex and higher disease burden;70 poor past attendance;71, 72 and younger age, single status, 
being less disabled, being employed, living in an urban setting, lower education level, 
possibly lower socioeconomic status, and possibly accessibility.61 However, the factors
associated with missing appointments may be different from those associated with 
laboratory completion.
We interviewed patients regarding missing monitoring, focusing on some of the
factors identified for appointments, in the qualitative study described in Chapter III, but
the small sample size there did not allow broad conclusions and did not include all of the
data available in the electronic medical record.
Therefore, we conducted a large quantitative retrospective study to identify both 
patient and provider characteristics associated with patient completion of laboratory 
testing ordered for high-risk medications in the ambulatory setting.
The specific aims were to examine the association between the following factors:
demographic information, including age and gender; number of currently prescribed 
study medications; frequency of medical appointments; and medical conditions, adjusting 
for provider factors affecting patient completion such as provider specialty training and 
frequency of prescribing this medication.
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C. Methods
i. Study Design and Setting
This study was also conducted within the Fallon Clinic, a large multispecialty 
group practice closely aligned with the Fallon Community Health Plan, a non-profit, 
Central Massachusetts-based integrated health care delivery system, as described in 
Chapter III. The practice uses the EpicCare Ambulatory electronic medical record (EMR) 
system (Epic, Verona, WI, Spring 2007 IU3 at the time of the study).
For this analysis, we included patients if they received care from the
multispecialty group practice, were 18 years or older, and had insurance coverage from
the health plan between January 1, 2007, and December 31, 2008. Patients had to be
continuously enrolled during the observation period and not residing in a long-term care
facility. Patients additionally had to have an order for a monitoring test placed by a
provider in the electronic record system within the time frame recommended for 
monitoring that drug-test pair.
ii. Selection of Study Medications
The medications included in this study, as in Chapters III and IV, were based on a
list of high-risk medications with recommended laboratory monitoring tests developed 
for a clinical decision support system that was intended to be embedded in the EMR. The
drug-test pair list is the same as in Chapter IV, Table 4.1.
As described in Chapter IV, each drug-test pair was additionally categorized 
based on the evidence basis for the test. In general, the level of evidence for medical
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guidelines widely varies, with possibly half of guideline recommendations based on low-
quality evidence.89 
iii. Medication Exposure
Data about medication exposure were derived from the prescription drug claims
of the health plan, while data about laboratory test orders were derived from the
multispecialty group practice electronic medical record. Use of claims data for 
medication exposure allowed for the measurement of medications actually filled at the
pharmacy, avoiding possible exposure misclassification by using EMR prescribing data
that may include prescriptions that were never filled or taken. In addition, the EMR 
includes “historical medications” which reflect over-the-counter medications and 
medications from outside providers but are inconsistently recorded across patients and 
providers. These medications are not included in the claims data and thus not included in 
this study, again meaning the possibility of not accounting for medications a patient is
taking but also decreasing the risk of erroneously considering a patient to be taking a
medication and thus underestimating appropriate testing. Completion of a test was also 
identified through the electronic record, using a field that uniquely identifies each ordered 
test and notes completion.
In cases where a patient had more than one new start of the same drug during the
study time frame (no refills or prescriptions for 180 days and then a new prescription), we
used the first prescription for that drug only.
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iv. Provider Factors
Provider data were collected from an internal provider demographic
database containing demographic information for past and present providers employed by 
the multi-specialty practice. As in Chapter IV, to maximize the dataset, we also included 
outside providers for whom we had specialty and gender. Provider and patient factors are
described in Table 5.1.
v. Key Variables
As in Chapter IV, variables included in this analysis were selected based on 
Anderson’s model of health services use which can be used to guide analyses of the
association between patient factors, physician factors, and health service utilization (i.e., 
laboratory monitoring of prescription medications). This model generally looks at the
behavior of patients and families, and it classifies predictors of behavior into three
categories: predisposing factors refer to demographic factors like age and gender as well
as family structure and health beliefs that affect service use; enabling factors include
resources that promote or inhibit use like income and health insurance; and needs factors, 
which comprise the illness and circumstances that necessitate use.30, 31 
Outcome variable:
Completion of ordered monitoring tests, dichotomized for each patient-drug-test 
combination, was the outcome variable.
Key predictor variables:
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Patient characteristics include age (continuous and by decade), gender, number of
study prescriptions (categorized into two and three groups), health status using a
Charlson score (score 0-16, index 0-2, and Romano variation), visit frequency 
(continuous and quartiles), and number of other study medications. Comorbidity was
measured using the Charlson score using ICD-9 codes from encounter data in the EMR 
via a tool in STATA using ICD9 codes.97 The Charlson score is correlated with 1-year 
mortality98 and is the most widely used comorbidity index.99 We examined both the
weighted index (0-16) and a categorical three-point index (0-2) defined as a weighted 
Charlson of 0, 1, or !2. The Romano adaptation of the Charlson score was also calculated 
in STATA from the disease-specific scores and also categorized into a dichotomous
variable (Romano "2 vs. Romano ! 3).100 The calculated variables were generated based 
on data in the EMR, including ICD-9 codes for diagnoses in the system.
Other variables:
Provider characteristics, including provider gender, age (continuous and by 
decade), and specialist versus primary care status, were included. Provider variables that
were not in or calculable from the EMR (such as full-time status and year of hire and 
graduation) were captured, deidentified, from the practice’s employment database.
As in Chapter IV, prescription characteristics, including drug, evidence for testing 
category (black box warning [BBW], other type of guideline, and testing for narrow
therapeutic window category), whether the drug had single or multiple recommended 
tests, and testing frequency were included. The BBW category was identified by 
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individually checking whether a given test addresses a warning via online databases
(labeling only relevant drug-test combinations as BBW, not by drug) with the caveat that
even BBW status is reported differently in different locations.94 
For analysis, we categorized many continuous variables into quartiles to help 
account for possible non-linearity. For example, we calculated quartiles for visit number 
per patient, drug prescribing frequency for providers, prescription number per provider, 
and number of patients per provider. We categorized age by decade, starting with patients
and providers below 40 and ending with providers >60 and patients >80, due to 
frequencies. We also categorized the number of drugs per patient (which ranged from 1 
to 9) as a dichotomous variable (one or more than one), and into three categories, 1, 2-4, 
and 5-9, to enable comparison to similar studies.96 
vi. Data Analysis
As in Chapter IV, prescriptions, laboratory orders, and completion status of tests
were extracted from the EMR for the time period in question. Each prescription, linked to 
scrambled IDs for both prescriber and patient, was then linked to laboratory orders for the
patient in question during the relevant time period, as well as to completion data for those
orders and to demographic and medical information for provider and patient.
We fit the data using a logistic regression models with a robust covariance
estimator (sandwich estimator) to adjust standard errors for clustering. This approach 
provides conservative nonparametric estimates.101-104 We first calculated robust standard 
errors based on clustering of medications within patient and separately performed 
calculations based on clustering within providers, ultimately clustering by provider for 
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more conservative estimates. Using this model, odds ratios (ORs) of factors associated 
with test completion were calculated.
Again, our modeling approach aimed to develop an explanatory model to identify 
factors that could be changed through intervention, rather than simply to obtain a best
predictive model.105 Therefore, unadjusted models examined relationships between each 
predictor and confounding variable with the outcome of test completion. Final
multivariable models included factors hypothesized to be associated with test ordering a 
priori, and factors associated with test ordering at the p<0.20 level in unadjusted analysis. 
We also calculated the c statistic, based on the area under the receiver operating 
characteristic (ROC) curve, to compare the multivariable logistic regression models.
Analyses were conducted in SAS 9.2 (SAS Institute, Cary, NC) and StataSE 
(Stata Statistical Software: Release 11.1, Stata Corporation, College Station, TX, USA).
D. Results
i. Patient Population and Use of Medications Requiring Laboratory Monitoring
Once ineligible patients, providers, and prescriptions were excluded and all
prescriptions were linked to patients and prescribing providers, I then excluded drug-test 
pairs for which a test was not ordered. The dataset included 27,802 patients and 251 
providers for a total of 55,592 drug-test pairs. As in the previous chapter, this included 
prescriptions for 34 high-risk medications or medication classes, some of which had 
multiple recommended tests, for a total of 60 drug-test combinations (Table 4.1). 
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Patients, with a mean age of 67, had on average 2 medications each (ranging from 1-9) as 
shown in Table 5.1 (not all information was available for all providers). 
ii. Provider Characteristics 
 When including only ordered tests, the number of patients and providers were 
slightly smaller than in the ordering analysis, but the distribution was similar. Providers 
had an average of 20 years since graduation, were 41% female, were mostly physicians 
(84.9%), and slightly more than half were primary care providers. Three-quarters worked 
fulltime and the mean number of prescriptions they had in the study was 238. 
Table 5.1: Summary of Provider and Patient Characteristics 
Providers  N, of 251 providers 
Mean age (years) 48.3 220 
Female 41.0% 249 
Physician vs. other kind of prescriber 84.9% 251 
Primary care physician (PCP) vs. specialist 56.3% 222 
Fulltime 76.4% 182 
Years of experience (years since graduation) 20.4 220 
Mean number of prescriptions in study 238 251 
   
Patients  27,802 
Mean age (years) 67.2  
Female 56.2%  
Study medications per patient 2.0  
   
Drug-test pairs  55,592 
New vs. chronic use 35.7% new  
Black box warning 15.9%  
iii. Unadjusted Analysis 
 Many variables were significantly associated with rates of test completion (Table 
5.2). Of particular interest were patient age (lower age associated with poorer completion, 
OR 2.33, p<0.001 for those over 70 compared to those under 40, with an increasing trend 
by decade); patients with more visits or higher Charlson index scores were more likely to 
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complete tests, though the Romano score was not correlated with completion; taking 
more than one drug increased completion (OR 1.45, p<0.001), being a new user of a 
prescription decreased completion (OR 0.36, p<0.001); and black box warning status of 
the prescription decreased completion (OR 0.56, p<0.001). Multiple tests for a drug 
increased completion for each test in that group (OR 1.48, p<0.001). Provider 
characteristics did not seem to play a major role in completion rates except for 
prescribing frequency, which increased the odds a patient would complete a test (OR 1.95 
for the highest quartile compared to the lowest). In addition, tests ordered by nurse 
practitioners (3% of the drug-test pairs) were associated with less completion (OR 0.73, 
p<0.05) than those ordered by physicians (95% of the drug-test pairs). 
Table 5.2: Unadjusted Characteristics Associated with Test Completion 
Patient characteristics Unadjusted Odds Ratio 
(OR) [95% Confidence 
Interval (CI)] 
Patient gender   
Male 1 [Reference] 
Female 1.06 [0.96 – 1.16] 
Patient age   
<40 years old 1 [Reference] 
40-50 1.14 [0.95 – 1.37] 
50-60 1.39 [1.19 – 1.63] 
60-70 1.90 [1.60 – 2.25] 
70-80 2.34 [2.00 – 2.75] 
≥80 2.32 [1.96 – 2.74] 
Number of patient visits (quartiles)   
0-5 visits 1 [Reference] 
6-10 visits 1.60 [1.44 – 1.79] 
11-18 visits 1.84 [1.64 – 2.06] 
≥19 visits 1.82 [1.65 – 2.02] 
Charlson score   
Charlson score = 0 1 [Reference] 
Charlson score = 1 1.19 [1.08 – 1.31] 
Charlson score ≥ 2 1.31 [1.19 – 1.45] 
Romano index  
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<3 1 [Reference] 
≥3 1.21 [1.10 – 1.34] 
Specific diseases, compared to not present   
Heart disease 1.13 [1.03 – 1.23] 
Dementia 1.31 [1.03 – 1.67] 
Number of study drugs patient is taking  
Single drug 1 [Reference] 
Multiple drugs 1.45 [1.33 – 1.58] 
Number of study drugs patient is taking   
1 drug 1 [Reference] 
2-4 drugs 1.49 [1.37 – 1.62] 
>5 drugs 1.14 [0.96 – 1.35] 
Provider characteristics   
Provider specialty  
Specialist 1 [Reference] 
PCP 0.97 [0.79 – 1.19] 
Provider type   
MD 1 [Reference] 
NP 0.72 [0.59 – 0.89] 
PA 0.94 [0.74 – 1.20] 
Provider frequency of prescribing this drug   
First quartile (once) 1 [Reference] 
Second quartile (2-5 times) 1.59 [1.08 – 2.34] 
Third quartile (6-46 times) 1.73 [1.22 – 2.45] 
Fourth quartile (≥47 times) 1.95 [1.35 – 2.81] 
Prescription characteristics   
Evidence for test  
Not BBW 1 [Reference] 
BBW 0.53 [0.47 – 0.59] 
Test frequency  
Yearly 1 [Reference] 
More frequent 0.82 [0.64 – 1.04] 
Number of tests recommended for this medication  
Single 1 [Reference] 
Multiple 1.48 [1.30 – 1.69] 
Prescription type  
Chronic use 1 [Reference] 
New use 0.36 [0.33 – 0.40] 
Abbreviations: BBW, black box warning; MD, medical doctor; NP, nurse practitioner; PA, physician 
assistant; PCP, primary care provider. 
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iv. Multivariable Analysis
In the multivariable analysis, we included a priori patient age, gender, and health 
status. We also thought test frequency and black box warning status could contribute to 
patient completion rates, and we hypothesized that provider specialty would affect patient
behavior. Other factors that were significant in the unadjusted analysis included provider 
type, number of drugs the patient was taking, new use versus chronic use, multiple versus
single tests for a drug, and number of drugs per patient.
Associated factors were again the number of drugs a patient was taking (fewer 
drugs meant a patient was less likely to complete a test), patient health status (measured 
by visit frequency: healthier were less likely to complete), patient age (younger were less
likely to complete), and to some extent, provider drug prescribing frequency (Table 5.3). 
Patient gender did not affect completion rates, and other provider factors we examined in 
the unadjusted model besides prescribing frequency were not associated with completion. 
Interestingly, when measured by Charlson index or Romano score rather than by visit
frequency, patient health status was not associated with completion, perhaps due to the
close interplay between age and Charlson index (when age was not accounted for, the
lower Charlson score was associated with higher completion). When the number of
patient drugs was categorized rather than dichotomized, the middle group (2-4 drugs) was
more likely to complete tests (OR 1.3, p<0.001), but those patients taking the most
medications (!5 drugs) were not significantly different in their completion rates than 
those taking only one. However, models including any of the proxies for health status had 
similar c statistics (0.68-0.69). Additionally, in all these models, BBW status, shown 
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elsewhere to be associated with higher ordering rates, was associated with lower rates of 
completion, between 0.52-0.54 (p<0.001). 
Table 5.3: Adjusted Model for Test Completion 
Variable N= 52407 
Adjusted OR [95% CI] 
Patient gender   
Male 1 [Reference] 
Female 0.99 [0.90 – 1.08] 
Patient age   
<40 years old 1 [Reference] 
40-50 1.02 [0.84 – 1.24] 
50-60 1.14 [0.96 – 1.37] 
60-70 1.45 [1.19 – 1.75] 
70-80 1.58 [1.33 – 1.89] 
≥80 1.52 [1.27 – 1.83] 
Number of patient visits (quartiles)   
0-5 visits 1 [Reference] 
6-10 visits 1.37 [1.22 – 1.53] 
11-18 visits 1.43 [1.27 – 1.60] 
≥19 visits 1.41 [1.25 – 1.59] 
Number of study drugs patient is taking   
Single drug 1 [Reference] 
Multiple drugs 1.26 [1.15 – 1.37] 
Provider specialty   
Specialist 1 [Reference] 
PCP 0.85 [0.71 – 1.03] 
Provider frequency of prescribing this drug   
First quartile (once) 1 [Reference] 
Second quartile (2-5 times) 1.31 [0.84 – 2.05] 
Third quartile (6-46 times) 1.58 [1.05 – 2.39] 
Fourth quartile (≥47 times) 1.49 [0.97 – 2.28] 
Evidence for test   
Recommended test 1 [Reference] 
BBW 0.52 [0.46 – 0.60] 
Guidelines 1.25 [1.07 – 1.46] 
Test frequency   
Yearly 1 [Reference] 
More frequent 1.01 [0.81 – 1.26] 
Number of tests recommended for this medication   
Single 1 [Reference] 
Multiple 1.46 [1.26 – 1.70] 
Prescription type   
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Chronic use 1 [Reference] 
New use 0.39 [0.36 – 0.42] 
Abbreviations: BBW, black box warning; CI, confidence interval; OR, odds ratio; PCP, primary care 
provider. 
E. Discussion 
 As with test ordering (Chapter IV), completion of laboratory monitoring was 
associated with patient age and patient visits, with younger age and fewer visits 
associated with less test completion. Being on fewer medications or having fewer tests 
recommended for a given medication also decreased the odds of completion. As older, 
sicker patients have more contact with the health care system, they are more often in 
situations that make it easy to get one or more tests completed. Interestingly, however, 
black box warning status, a proxy for the seriousness of the potential adverse event 
caused by a drug, was associated with decreased completion, though it was associated 
with increased ordering. It is concerning that patients are less likely to complete testing 
for these higher-risk medications, particularly since we have shown that providers order 
the tests at higher rates. Interventions should target patients taking these medications. 
 We also found that new users of a medication were much less likely to complete 
ordered tests, perhaps due to lack of familiarity with the test process or the reasons 
behind the test. However, test frequency (more than yearly compared with yearly 
recommendations) was not associated with completion. This can be perhaps explained 
because this factor reflects the recommended frequency of testing, not the actual ordered 
frequency. The latter is more likely to affect patient behavior, but we only included one 
test per prescription. A follow-up study is underway which accounts for tests that need to 
be repeated on multiple occasions. 
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i. Adherence
Patient adherence poses challenges to ideal medical treatment in a number of
ways. First of all, patients often do not take prescribed medications: depending on drug, 
one study showed variation between 36.8% (gout patients) to 72.3% (hypertension).28 
Our study showed relatively high completion rates, though still less than ideal, 
particularly given the large number of patients on some of these medications (for 
example, ordered AST tests for statins were not completed more than 10% of the time, 
thus affecting almost 1,400 patients in the one year in our dataset).
Just as improving medication adherence improves outcomes and reduces costs,134 
improving adherence to appointments and laboratory monitoring tests, as we have seen, 
has the potential for reducing adverse events, as well as reducing the costs associated 
with them.
Attendance at appointments has been shown to vary with factors associated with 
both patients and providers, with non-attendance ranging from 5-39% in the literature.71,
72 However, the provider factors tend to actually be system factors like waiting time and 
timing of appointment rather than actual provider characteristics,107, 135, 136 similar to our 
finding of limited association with provider factors.
As with attendance at appointments, we found that younger patients and healthier 
patients, as indicated by lower visit frequency or taking only one medication, were less
likely to complete their testing. Thus interventions that have been successful in 
improving attendance at appointments70, 137-140 might also be effective at improving 
laboratory monitoring. However, an important distinction is that laboratory tests are
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generally ordered for a time frame rather than for a specific time and date: sending 
reminders near the “due date” for the test (in our system, set up as an “expected 
completion date”) could improve completion.
Identifying early on these patients at risk for non-completion could allow for 
closer monitoring of their lab testing patterns and earlier intervention when a test is
missed. Alerting provider regarding patient non-completion could also be effective, 
particularly for patients on medications with black box warnings, as the provider ordered 
a test and clearly considered it important.
ii. Tools to Improve Laboratory Monitoring
While use of EMRs, particularly in the ambulatory setting, is far from
universal,141 the data stored in them allow for very targeted and scheduled interventions
to be sent to patients, identifying targets for telephone, letter, or electronic
communication. Furthermore, the increase in availability and patient use of personal
health records (PHRs), often linked to institutional EMRs, allows patients to access the
same data as their providers, including test results, upcoming scheduled appointments
and tests, and overdue or missed events. These tools allow for targeting and intervention 
in a way impossible before. Furthermore, for identification and research, EMRs are
central for distinguishing failure to order from failure to complete testing. However, 
simple presence of an EMR certainly does not guarantee better outcomes, at least on 
specific quality indicators,142 and it is even harder to make conclusions about overall
quality and outcomes when severe adverse events, though relatively common, have low
absolute frequencies, even for high-risk medications such as those included in this study, 
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and are often difficult to directly attribute to lack of monitoring; we would need an even 
larger sample size to study such outcomes.
We discussed the effectiveness of reminders to providers in Chapter IV. 
Interventions directed at improving test completion or those directed at patients have
similarly inconsistent results. Reminders for outpatient appointments,140 immunization,143 
and preventive screening,144 have been found to be somewhat effective, depending on 
design. Telephone reminders in some cases were found to be most effective or most cost-
effective.143, 144 Though most studies directed at patient attendance use letters or 
telephone calls to patients, including those specifically targeting laboratory testing,9, 13, 24 
they increasingly rely on computers to customize those alerts and automate the
intervention.
We recommend using the EMRs to identify patients for reminders, whether 
electronic, telephonic, or by letter, when a scheduled test is approaching its “expected 
completion date,” which should be a required field for the provider. Patients who have
been using a PHR should be contacted that way. Patients who are younger or healthier, 
who are taking fewer medications, or who have missed a laboratory test should be
prioritized for contact and should be contacted through their preferred modality and 
possibly through more than one.
Since these data were studied, we have initiated an automated calling system at
our site, based on data in the EMR, that is currently being evaluated for effectiveness, 
with results to be reported in future publications.
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iii. Strengths and Limitations
As above, the patients receiving care from our practice are representative of the
population of central Massachusetts. Although the multi-specialty practice is similar to 
many similar healthcare provider groups across the US, it is different in that it is an 
integrated health care system and it is one of the early providers to have full
implementation of electronic medical records and computerized physician order entry. As
in Chapters III and IV, we may have missed monitoring that was done outside of the
system, and we were unable to confirm patient adherence to drugs and were unable to 
identify patients who did not complete tests because they were no longer using the
medication for whatever reason. Lastly, lack of completion may not be due to patient
non-adherence. For example, patients may be told not to complete the test because of
testing done elsewhere without the electronic record changed to reflect that through order 
cancellation (there is little motivation for a provider to cancel an pending order if the
patient is not expected to complete it). However, the largest factor in completion is likely 
the patient, and therefore this model focuses on identifying patient characteristics that
drive completion, as well as provider characteristics that have an effect. Lastly, this study
only analyzes factors associated with completion of testing ordered for high-risk 
medications in the ambulatory setting. Patients may be more likely to complete testing for 
orders generated as a result of specific symptoms and this study does not analyze overall
completion rates.
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iv. Future Research
Already underway are interventions targeting patients by phone, by mail, and 
through electronic means to improve test completion. Though past interventions of this
type have had varying effectiveness,23 improved design and analysis of these types of
interventions could have great impact.
Prior non-attendance has been shown to be associated with appointment non-
attendance29 and may be a helpful predictive factor in laboratory test non-completion; the
population of patients who in the past have not shown up for ordered tests, using 
historical data to identify them, could be another target for future research.
v. Conclusion
Younger, healthier patients may be more at higher of not completing ordered 
laboratory tests, along with patients with medications that do not have black box 
warnings, which are considered particularly risky. Providing reminders to providers to 
order tests for high-risk medications is not on its own sufficient, as patients do not
reliably complete ordered tests. Patients, particularly those at high risk of not completing 
tests, should be targeted directly for reminders or other interventions, ideally through a
modality of their choice, in order to maximize adherence and prevent adverse drug 
events.
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CHAPTER VI
DISCUSSION AND CONCLUSIONS
A. Summary of Research Findings
Little research has described factors contributing to patient completion of lab 
testing, and even less has focused on physician factors associated with ordering. This
thesis has contributed to the literature with a number of new research findings.
In Chapter II, I reviewed the interventions that have been attempted thus far to 
improve laboratory monitoring in the ambulatory setting using health information 
technology. These attempts have had varied success and the best design for future
interventions is not clear. However, focusing on the most important types of monitoring 
might make a difference.
In Chapter III, I presented a mixed-method study in which I found that completion 
rates significantly vary by drug-test pair, in this case for patients on chronic doses of
frequently prescribed medications in the ambulatory setting, ranging from 37.90% 
(Valproic Acid-AST) to 96.84% (Niacin-AST). I showed that a part of non-completion 
could be attributed to provider non-ordering (rates varying from 1.1% in the Niacin-AST 
drug-test pair to 51.6% in the Valproic Acid-Valproic Acid level drug-test pair), while
patient non-completion accounted for the rest (varying from 2.13% for Niacin-AST to
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24.19% for Valproic Acid-AST). In structured interviews with patients, we found that
most patients listed few barriers to completion, denying that various systems factors like
transportation or convenience were barriers to completing tests. They generally attributed 
missing tests to forgetting. I concluded that well-timed reminders, customized by patient
preference for delivery method, could increase attendance in populations like the one we
interviewed. An intervention is now underway to test that hypothesis, with patients
receiving phone calls before an ordered test is expected to be completed.
In Chapter IV, I reported results of an analysis examining factors associated with 
ordering of laboratory monitoring. The model suggested an association between lower 
ordering rates and the following factors: lower patient age, lower visit frequency, lack of
black box status, and smaller provider panel size. Tests that are recommended for more
frequent ordering were also associated with lower ordering rates. When stratified by 
black box status, specialists were much more likely to order a test for the higher-evidence
drug-test combinations than primary care providers, a distinction not seen in the
combinations without that level of evidence.
I then reported a similar analysis looking at factors associated with completion in 
Chapter V. For test completion, younger patients and those with fewer visits or fewer 
medications were again less likely to complete tests, but comorbidity was not associated 
with completion, and the evidence base was actually associated with a lower odds ratio 
for completion. No provider factors were significantly correlated with the outcome of test
completion in multivariable analysis.
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Overall, primary care doctors have larger patient panels (in this dataset, almost 10 
times as many patients) and prescribe a greater number of different drugs (13 versus 5) 
than specialists on average. While this increased prescribing may improve familiarity and 
thus quality of care in some cases, the drug variety may also make it more difficult for 
primary care providers to be familiar with guidelines about every medication. In addition, 
older patients and those with more interaction with the health care system seem more
likely to get recommended testing ordered and completed. 
Another important finding is the quite different behavior for those drug-test 
combinations with black box warnings (BBWs) from the Food and Drug Administration. 
While adherence to these warnings is known to be variable and low and the level of
evidence is uneven within the drug-test combinations with BBWs, we saw a strong 
association between these levels of warnings and higher testing rates, while we found less
completion for drug-test combinations with BBWs.
These results should direct future interventions as we continue to work to improve
laboratory monitoring for high-risk medications in the ambulatory setting and to improve
medication safety for all patients.
B. Strengths and Limitations
The main limitation of this study is its lack of generalizability. Though we have
shown that the population in our dataset is similar to the national population in many 
ways, and the multi-specialty practice from which we extracted the data is similar to 
many similar healthcare provider groups across the US, it is different in that it is an 
integrated health care system and it is one of the early providers to have full
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implementation of electronic medical records and computerized physician order entry. 
Indeed, little research thus far has evaluated multifunctional commercially developed 
systems like Epic,22 and thus the applicability of our findings to smaller practices is
unknown.
However, this dataset and study have many strengths. Using a fully integrated 
health care record, along with claims data, allowed us to achieve the linking of laboratory 
and pharmacy recommended to allow for quality improvement.19 
Despite this integrated and relatively complete data source, I did encounter 
unexpected challenges using data not intended for research purposes. Some of these were
true of all data not intended for research,17 while others were specific to this study. For 
example, in this electronic record system, orders are often duplicated when intended only 
once or not canceled when not intended to be completed; similarly, prescription orders
are frequently duplicated and medications are often not appropriately discontinued in the
system; patients or provider data is often incomplete, or identification is incorrect or 
confusing for research (such as cases where providers were listed in different places with 
different specialties because of certification in both); fields are defined in ways that may 
work clinically but can be limiting for research, such as allowing for free text; and many 
other problems. As always, human behavior is more complicated than the computer 
systems can account for: when a provider prescribes twice the dose so the patient can 
save money and take half a pill daily, it helps the patient but flummoxes researchers.
Challenges like this face anyone using data meant for administrative purposes for 
research, not just electronic or electronic medical record (EMR) data, and it required 
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extensive clarification and cleaning of the data. Furthermore, due to limitations in 
software, we were unable to correlate address information to get the socioeconomic status
we were hoping for. Race and primary language information was not available.
We used claims data for prescriptions to overcome the problem of drugs
prescribed but not ever filled at the pharmacy, but we had little recourse with some of the
other data problems. For example, and importantly, laboratory tests are ordered without
necessarily indicating the reason for the test. In some cases, a test that serves as a
monitoring test for a specific medication may be ordered for another reason, such as
symptoms or preparing for a procedure. These tests were not differentiated in our data
from those done for monitoring.
However, the advantages were significant, as we were able to include various
factors often not present in single datasets. Unlike other studies of laboratory monitoring, 
this thesis reports on work that was able to analyze both ordering rate and completion 
rates for a large population using electronic record data. By separating ordering from
completion, as has rarely been done for this topic, I could identify specific associations
for each behavior. Epic, one of the oldest and most popular electronic record systems in 
use in this country, has been used at this clinic for many years, allowing a longer 
timeframe for analysis than at institutions with recent electronic record implementation. 
The work was strengthened by a qualitative analysis of patient reasons for missing 
laboratory tests (Chapter III): for the first time, patients were directly asked why they had 
missed monitoring tests, identifying reasons beyond what was contained in the electronic
record. Our interventions have now been directed at the causes for missing tests that were
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identified by our patients, specifically aiming to remind patients regarding ordered testing 
when it is not associated with a specific appointment.
C. Future Directions
i. Changing Behavior
This work does not answer the difficult question of how to change provider 
practice or patient behavior. However, once the best target populations are identified, 
interventions to change behavior are the next step.
Potential impact of reminders to providers
Past research has shown dismal adherence to guidelines, with increases facilitated 
by some interventions,23, 88, 120, 145 though still not reaching ideal levels of adherence. Like
patients, providers do not think they commit laboratory monitoring errors and “were
surprised at the error rates reported in the literature.”26 They are open to computerized 
alerts26 and to clinical decision support in general if it is designed well, not too sensitive, 
and minimally interruptive.128-130 Primary care providers believe that they can comply 
better with guidelines given electronic clinical reminders (79% in one survey131) although 
they may be less likely to do so when behind or when managing complicated patients.132 
The reasons for provider non-adherence have been classified into five categories
including concerns for a patient’s ability to adhere and concerns about side effects to 
patients of recommended treatment.114 To change provider behavior, however, the
literature suggests there are five main strategies: “education, feedback, rationing, 
financial incentives, and penalties.”146 However, few interventions have thus far been 
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147 
shown to effectively improve ambulatory laboratory monitoring. Most interventions
focus on the potential of reminders50 particularly when presented at the right time,38, 120,
.
However, we have seen the complication of the lack of evidence that guidelines
actually improve patient outcomes, perhaps influencing provider behavior against certain 
interventions.112 In some cases, there is explicit skepticism among providers about the
evidence base of guidelines and their applicability , and even their motivation (cost 
containment rather than patient care).118 This is not unfounded skepticism: indeed, 
possibly more than half of guidelines are based on poor evidence.89 Similarly, studies of
clinical decision support systems that have shown change in provider behavior have not
shown the same effect on patient outcomes.126 Our data set was not large enough to 
demonstrate an impact on outcomes, but this kind of research—examining the impact of
lack of test ordering and completion on hospitalizations and mortality—would greatly 
add to our understanding of not just how to promote guidelines but which are worth 
promoting.
Potential power of reminders to patients
Patients also stand to benefit from timely reminders. Some reminder programs
have been shown to work. Regarding preventive care, for example, letters, phone calls, 
and enhanced reminders all effective at increasing mammography rates, with automated 
phone calls being most effective and low-cost.144 Similarly, for immunizations, a recent
review of 47 studies found that postcards, letters, telephone or auto-dialer calls were all
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effective in improving immunization rates, though they found that phone calls were the
most expensive.143 
Partly as a result of the findings of this thesis, our group has begun automated 
phone call reminders to patients as well as clinical decision support-based reminders to 
prescribers. We hope to report on the effectiveness of these interventions in the near 
future.
ii. Role of Health Information Technology (HIT)
A major challenge of this kind of research is, as noted elsewhere, that the
evidence for laboratory monitoring is not consistently strong. Focusing on those drug-test 
combinations shown to be most important for safety will yield the largest benefit, but the
current guidelines are often much broader. Thus better data collection is critical to 
determining the most important targets, and then intervening to improve monitoring 
focusing on those targets will be most effective.
HIT will play a central role in this data collection as well as in any interventions
to improve laboratory monitoring. In the first chapter, I discussed the research that has
been done so far on such HIT interventions. My systematic review,23 reprinted here as
Chapter II, suggested a promising role for these tools, limited by implementation as well
as analysis of the interventions.
Overall, HIT has been shown to improve quality by increasing adherence to 
guidelines, improving disease surveillance, and decreasing medication errors.22 Another 
recent review showed predominantly positive results of health information technology.148 
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However, the prevalence of electronic records in the United States is still quite low.141, 149,
150 
The first step in improving care is using the data we already have. The linking of
laboratory data to pharmacy data is not at all universal, but it holds great potential for 
improved medical care as well as research, even before implementation of further alerts
or other structured interventions.18, 19 
Once the data is available in an electronic medical record, research offers some
guidance for the most promising interventions. Default settings are very powerful and can 
affect provider behavior.21 Tiered alerts121 and interruptive alerts151 have been shown to 
lead to better provider adherence in general. The computerized format also allows for 
further customizations, so that only certain providers can prescribe certain medications or 
order certain tests. Further work on laboratory monitoring-specific alerts is needed, 
however. Much of the research thus far on HIT and laboratory monitoring specifically 
and for these systems in general has come from only four large institutions, limiting 
generalizability to the broader setting.22 This suggests the need for testing more widely, 
especially in vendor systems.
Broader implementation of electronic records, which is occurring under the
influence of the 2009 American Recovery and Reinvestment Act, will improve the
nation’s ability to tract laboratory testing. We recommend tracking test orders and test
completion separately and then reporting back to providers as well as institutions so that
they are aware of their test ordering rates compared to the recommendations and perhaps
compared to their colleagues. Orders and prescriptions should be clearly linked to 
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specific physicians, and future research should address the fact that the prescriber is not
necessarily the person ordering the tests. When tests are ordered but not completed, 
ordering providers could be alerted in addition to sending alerts to patients,33 though the
effectiveness of such an intervention to affect completion is thus far unknown. 
Contacting patients through their own selected modality (phone, email, personal health 
record) could also improve completion rates.
iii. Cost
No discussion of health care quality can ignore the issue of cost. With more than 
16% of the United State’s gross domestic product (GDP) going to health care as of
2008,152 cost of care should be considered in any health policy recommendation. This
study did not measure the cost of adverse events resulting from inadequate testing nor did 
we examine the costs of unnecessary tests (though this is also a problem, more often in 
the inpatient setting,146 with the potential for great savings153). As we better identify the
evidence supporting testing and the adverse events caused as a result of failure to do so, 
we will then be better able to assess the cost of under-monitoring as well as the waste
involved in over-monitoring.
D. Final Conclusions
“Test non-completion decreases quality of care.”33 
Our data add to the knowledge about patients who miss laboratory tests and where
along the prescribing-to-testing path interventions may be most promising and for whom. 
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We also identify the limitations of current data, with the hope that future systems will
better gather data (including indications for testing and more detailed patient and provider 
information) to allow even more targeted work. We look forward to a healthcare system
in which guidelines are supported by strong evidence and providers are given the tools to 
implement them consistently, while patients are supported to participate in their own care
to achieve the best outcomes possible.
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